fluorouracil has been researched along with Stomatitis in 371 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Stomatitis: INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
| Excerpt | Relevance | Reference |
|---|---|---|
| "to evaluate the effect of oral cryotherapy compared to physiological serum on the development of oral mucositis in outpatient cancer patients using the 5-fluorouracil antineoplastic agent." | 9.34 | Effect of cryotherapy in preventing mucositis associated with the use of 5-fluorouracil. ( Aguiar, MIF; Alves, NP; Lopes, TSS; Oliveira, PP; Rodrigues, AB; Silva, RA; Vitorino, WO, 2020) |
| "We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab." | 9.17 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013) |
| "We measured the effectiveness of the prophylactic administration of a polaprezinc suspension dispersed in sodium alginate solution (P-AG) by dividing it into two courses in the same patients, and measured the stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy." | 9.15 | [Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer]. ( Fujiki, Y; Hama, T; Hatake, K; Ishibashi, M; Kawakami, K; Kawata, K; Mishima, Y; Nemoto, M; Sugisaki, T; Takahashi, S; Yokoyama, M, 2011) |
| "Stomatitis is a common adverse effect of intravenously infused 5-fluorouracil (5FU)." | 9.12 | Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. ( Kalofonos, Ch; Naxakis, S; Papadeas, E; Riga, M, 2007) |
| " Oral glutamine supplements (OGS) may have a role in the prevention of chemotherapy-induced mucositis/stomatitis." | 9.12 | The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. ( Choi, K; Jeon, WK; Kim, JW; Lee, SS; Lim, SY; Oh, SJ; Oh, TY, 2007) |
| "To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy." | 9.12 | Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. ( Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 9.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)." | 9.11 | A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 9.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting." | 9.10 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002) |
| "The present study was conducted to evaluate the effect of allopurinol spray on stomatitis induced by chemotherapy for esophageal cancer." | 9.10 | [The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs]. ( Fujii, E; Hanawa, T; Ito, A, 2002) |
| "The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer." | 9.09 | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 9.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 9.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer." | 9.08 | Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995) |
| "A clinical trial was conducted in order to evaluate the anti-tumor effect and toxicity of a continuous infusion of 5-fluorouracil (5-FU) for metastatic colorectal cancer." | 9.08 | Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer. ( Kondo, H; Ohkura, H; Saito, D; Shimada, Y; Shirao, K; Sugano, K; Yamao, T; Yokota, T; Yoshida, S, 1995) |
| "No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 9.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
| "A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV." | 9.08 | A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996) |
| "Stomatitis is a major dose-limiting toxicity of bolus fluorouracil (5FU)-based chemotherapy regimens, despite the use of oral cryotherapy." | 9.08 | Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. ( Camoriano, J; Gerstner, JB; Ghosh, C; Hatfield, AK; Loprinzi, CL; Michalak, JC; Novotny, PJ; Quella, SK; Schaefer, PL; Sloan, J; Steen, PD; White, DF, 1997) |
| "Stomatitis caused by a combined chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP) is a serious problem in the course of treatment for patients with oral carcinoma." | 9.08 | [Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)]. ( Kumagai, S; Mori, S; Morikawa, H; Sakaki, K; Sato, A; Song, ST, 1997) |
| "Recently, a randomised study demonstrated the utility of oral cooling (cryotherapy) in the prevention of 5-fluorouracil (5FU)-induced stomatitis." | 9.07 | Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. ( Cascinu, S; Catalano, G; Fedeli, A; Fedeli, SL, 1994) |
| "This study was aimed at assessing the efficacy of allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis." | 9.07 | Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. ( Moroni, M; Nastasi, G; Porta, C, 1994) |
| "The authors previously reported that 30 minutes of oral cryotherapy inhibits 5-fluorouracil (5-FU)-induced stomatitis." | 9.07 | A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. ( Finck, G; Glaw, KC; Hatfield, AK; Iverson, RK; Kunselman, SJ; Lee, JK; Lifsey, D; Loprinzi, CL; Rocke, LK; Stevens, BA, 1993) |
| "We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer." | 9.07 | Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992) |
| "Pursuant to a promising report suggesting that an allopurinol mouthwash could have a protective effect against 5-fluorouracil (5-FU)-induced stomatitis, the authors performed a randomized, placebo-controlled, double-blind, crossover study." | 9.06 | A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. ( Athmann, LM; Burnham, NL; Cianflone, SG; Cross, M; Dose, AM; Etzell, PS; Gainey, DK; Hagen, L; Loprinzi, CL; Therneau, TM, 1990) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 9.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers." | 8.98 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 8.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin." | 8.86 | Interaction between capecitabine and brivudin in a patient with breast cancer. ( Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P, 2010) |
| " A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia." | 8.83 | Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006) |
| "A meta-analysis of six North Central Cancer Treatment Group (NCCTG) trials involving patients receiving their first ever fluorouracil (5-FU)-based chemotherapy was undertaken to explore the association of sex with reports of the incidence and severity of stomatitis." | 8.80 | Sex differences in fluorouracil-induced stomatitis. ( Barton, DL; Loprinzi, CL; Nair, S; Novotny, PJ; Okuno, S; Sloan, JA, 2000) |
| "Glutaryl melatonin exhibited mild anti-candidiasis and anti-inflammatory properties." | 7.96 | Glutaryl Melatonin Niosome Gel for Topical Oral Mucositis: Anti- Inflammatory and Anticandidiasis. ( Daduang, J; Damrongrungruang, T; Mahakunakorn, P; Panpitakkul, P; Panyatip, P; Priprem, A; Puthongking, P; Sangchart, P; Somudorn, J; Uthaiwat, P, 2020) |
| "We used 90 mice of the CF-1 strain in which oral mucositis was induced using a protocol with 5-fluorouracil (5-FU) chemotherapy." | 7.96 | Cannabidiol on 5-FU-induced oral mucositis in mice. ( Borghetti, RL; Cherubini, K; Cuba, LF; de Figueiredo, MAZ; Guimarães, FS; Salum, FG, 2020) |
| " In this study, we investigated spontaneous pain and mechanical allodynia in a preclinical model of oral ulcerative mucositis after systemic administration of the chemotherapy drug 5-fluorouracil, using our proprietary pain assay system for conscious rats." | 7.83 | Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil. ( Goto, T; Harano, N; Hitomi, S; Inenaga, K; Inoue, H; Ito, M; Matoba, M; Miyano, K; Nodai, T; Ono, K; Uezono, Y; Watanabe, S; Yamaguchi, K, 2016) |
| "5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer." | 7.70 | Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 7.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | 7.67 | Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| "The authors assessed the value of protracted low-dose 5-fluorouracil (5-FU) infusion (250 mg/m2/day) in refractory breast cancer." | 7.67 | 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. ( Holmes, FA; Hortobagyi, G; Jabboury, K, 1989) |
| "Sixty breast cancer patients undergoing an FEC60 regimen were enrolled, 37 patients completed the study." | 6.78 | The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013) |
| " Patients exhibited high compliance in dosing administration." | 6.74 | Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 6.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "Thirty-two patients (76%) had no oral mucositis." | 6.68 | Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. ( Chan, WK; Chen, KY; Chen, SY; Chi, KH; Law, CK; Shu, CH; Yen, SH, 1995) |
| "Mucositis is a common toxicity of cancer chemotherapy." | 6.68 | Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. ( Anderson, PM; Skubitz, KM, 1996) |
| "Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells." | 6.41 | Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002) |
| "Chemotherapy-induced oral mucositis (COM) is a common adverse effect of cancer chemotherapy." | 5.91 | Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis. ( Hira, D; Imai, S; Ito, M; Itohara, K; Kagawa, M; Matsubara, K; Nakagawa, S; Nakagawa, T; Ogihara, T; Terada, T; Yamanaka, R; Yonezawa, A, 2023) |
| "The current idea of how oral mucositis (OM) develops is primarily based on hypotheses and the early events which precede clinically established OM remain to be demonstrated." | 5.91 | Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats. ( Aydogdu, Ö; Dankis, M; Jontell, M; Walladbegi, J; Winder, M, 2023) |
| "Elental reduced oral mucositis and dermatitis more effectively than dextrin in the animal model." | 5.48 | Elemental Diet Accelerates the Recovery From Oral Mucositis and Dermatitis Induced by 5-Fluorouracil Through the Induction of Fibroblast Growth Factor 2. ( Ferdous, T; Harada, K; Kobayashi, H; Ueyama, Y, 2018) |
| "Population-based studies of adverse events are scarce." | 5.38 | Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. ( Cen, P; Du, XL; Liu, C, 2012) |
| "to evaluate the effect of oral cryotherapy compared to physiological serum on the development of oral mucositis in outpatient cancer patients using the 5-fluorouracil antineoplastic agent." | 5.34 | Effect of cryotherapy in preventing mucositis associated with the use of 5-fluorouracil. ( Aguiar, MIF; Alves, NP; Lopes, TSS; Oliveira, PP; Rodrigues, AB; Silva, RA; Vitorino, WO, 2020) |
| "However, stomatitis is one of the limiting side effects." | 5.28 | Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes. ( Elzawawy, A, 1991) |
| "Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs." | 5.27 | Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. ( Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C, 2018) |
| "We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab." | 5.17 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013) |
| "The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer." | 5.17 | FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. ( Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F, 2013) |
| "We measured the effectiveness of the prophylactic administration of a polaprezinc suspension dispersed in sodium alginate solution (P-AG) by dividing it into two courses in the same patients, and measured the stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy." | 5.15 | [Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer]. ( Fujiki, Y; Hama, T; Hatake, K; Ishibashi, M; Kawakami, K; Kawata, K; Mishima, Y; Nemoto, M; Sugisaki, T; Takahashi, S; Yokoyama, M, 2011) |
| "Stomatitis is a common adverse effect of intravenously infused 5-fluorouracil (5FU)." | 5.12 | Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. ( Kalofonos, Ch; Naxakis, S; Papadeas, E; Riga, M, 2007) |
| " Oral glutamine supplements (OGS) may have a role in the prevention of chemotherapy-induced mucositis/stomatitis." | 5.12 | The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. ( Choi, K; Jeon, WK; Kim, JW; Lee, SS; Lim, SY; Oh, SJ; Oh, TY, 2007) |
| "To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy." | 5.12 | Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. ( Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 5.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)." | 5.11 | A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 5.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting." | 5.10 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002) |
| "To test the activity of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in patients with colorectal cancer treated with adjuvant 5-fluorouracil (5-FU) plus leucovorin (LV) and suffering from mucositis." | 5.10 | Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature. ( Colarusso, D; Manzione, L; Rosati, G; Rossi, A, 2003) |
| "The present study was conducted to evaluate the effect of allopurinol spray on stomatitis induced by chemotherapy for esophageal cancer." | 5.10 | [The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs]. ( Fujii, E; Hanawa, T; Ito, A, 2002) |
| "Diarrhea is dose-limiting with weekly 5-fluorouracil (5-FU) plus high-dose leucovorin (LV)." | 5.09 | Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ( Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Rustum, YM, 1999) |
| "The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer." | 5.09 | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 5.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 5.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer." | 5.08 | Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995) |
| "A clinical trial was conducted in order to evaluate the anti-tumor effect and toxicity of a continuous infusion of 5-fluorouracil (5-FU) for metastatic colorectal cancer." | 5.08 | Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer. ( Kondo, H; Ohkura, H; Saito, D; Shimada, Y; Shirao, K; Sugano, K; Yamao, T; Yokota, T; Yoshida, S, 1995) |
| "No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 5.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
| "Stomatitis has been found to be a major dose-limiting toxicity from bolus 5-fluorouracil-based (5-FU) chemotherapy regimens, despite the use of oral cryotherapy." | 5.08 | Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. ( Bartel, J; Clemens-Schutjer, D; Fidler, P; Hayes, DL; Lee, JK; Leitch, JM; Loprinzi, CL; Michalak, JC; Novotny, P; O'Fallon, JR, 1996) |
| "A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV." | 5.08 | A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996) |
| "Stomatitis is a major dose-limiting toxicity of bolus fluorouracil (5FU)-based chemotherapy regimens, despite the use of oral cryotherapy." | 5.08 | Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. ( Camoriano, J; Gerstner, JB; Ghosh, C; Hatfield, AK; Loprinzi, CL; Michalak, JC; Novotny, PJ; Quella, SK; Schaefer, PL; Sloan, J; Steen, PD; White, DF, 1997) |
| "Stomatitis caused by a combined chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP) is a serious problem in the course of treatment for patients with oral carcinoma." | 5.08 | [Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)]. ( Kumagai, S; Mori, S; Morikawa, H; Sakaki, K; Sato, A; Song, ST, 1997) |
| "Recently, a randomised study demonstrated the utility of oral cooling (cryotherapy) in the prevention of 5-fluorouracil (5FU)-induced stomatitis." | 5.07 | Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. ( Cascinu, S; Catalano, G; Fedeli, A; Fedeli, SL, 1994) |
| "Pharmacokinetics of total platinum, 5-fluorouracil, l-folinic and d-folinic acid, and 5-methyltetrahydrofolate were studied in plasma from nine patients with advanced colorectal cancer treated with oxaliplatin (20 mg/m2/day), 5-fluorouracil (600 mg/m2/day), and folinic acid (300 mg/m2/day)." | 5.07 | Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. ( Bastian, G; Brienza, S; Comisso, M; Etienne, MC; Lévi, F; Massari, C; Metzger, G; Milano, G; Misset, JL; Touitou, Y, 1994) |
| " Leukopenia was severe in the first two steps of treatment, with WHO grade IV toxicity occurring in 41% of patients; however, this decreased to 10% when vindesine was deleted from the chemotherapy regimen in the last two steps." | 5.07 | Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study. ( Bauer, J; Bernasconi, S; Leyvraz, S; Monnier, P; Pasche, P, 1994) |
| "This study was aimed at assessing the efficacy of allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis." | 5.07 | Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. ( Moroni, M; Nastasi, G; Porta, C, 1994) |
| "The authors previously reported that 30 minutes of oral cryotherapy inhibits 5-fluorouracil (5-FU)-induced stomatitis." | 5.07 | A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. ( Finck, G; Glaw, KC; Hatfield, AK; Iverson, RK; Kunselman, SJ; Lee, JK; Lifsey, D; Loprinzi, CL; Rocke, LK; Stevens, BA, 1993) |
| "We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer." | 5.07 | Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992) |
| "148 patients with advanced untreated colorectal cancer were randomised to receive a weekly bolus of 5-fluorouracil (5-FU) 600 mg/m2 alone, with or without leucovorin (LV) 500 mg/m2." | 5.07 | Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. ( Canobbio, L; Fassio, T; Gallo, L; Guglielmi, A; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Venturini, M; Vidili, MG, 1992) |
| "Pursuant to a promising report suggesting that an allopurinol mouthwash could have a protective effect against 5-fluorouracil (5-FU)-induced stomatitis, the authors performed a randomized, placebo-controlled, double-blind, crossover study." | 5.06 | A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. ( Athmann, LM; Burnham, NL; Cianflone, SG; Cross, M; Dose, AM; Etzell, PS; Gainey, DK; Hagen, L; Loprinzi, CL; Therneau, TM, 1990) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 5.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "A randomized control trial study was carried out to evaluate the effect of allopurinol mouth wash on stomatitis induced by chemotherapy in gynecologic patients." | 5.06 | [Prevention of stomatitis induced by anti-cancer drugs]. ( Dozono, H; Ishibashi, M; Miwa, K; Motoya, T; Nagata, Y; Nakamura, K; Nakamura, S; Shinmura, R, 1989) |
| "5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers." | 4.98 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 4.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy." | 4.87 | Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. ( Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM, 2011) |
| "A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin." | 4.86 | Interaction between capecitabine and brivudin in a patient with breast cancer. ( Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P, 2010) |
| "We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer." | 4.83 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006) |
| " A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia." | 4.83 | Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006) |
| "A meta-analysis of six North Central Cancer Treatment Group (NCCTG) trials involving patients receiving their first ever fluorouracil (5-FU)-based chemotherapy was undertaken to explore the association of sex with reports of the incidence and severity of stomatitis." | 4.80 | Sex differences in fluorouracil-induced stomatitis. ( Barton, DL; Loprinzi, CL; Nair, S; Novotny, PJ; Okuno, S; Sloan, JA, 2000) |
| " Pain is measured by facial grooming behavior stimulated by capsaicin, the alternation of body weight and food intake was also recorded to reflect the OM pain." | 4.31 | Sprayable NAHAO® hydrogel alleviates pain and accelerates rat oral mucositis wound healing. ( Ma, H; Mao, R; Tang, Y; Yan, H; Zhang, Y; Zhao, Y, 2023) |
| "In this study, the oral mucosa of mice was burned with 90% phenol and intraperitoneal injection of 5-fluorouracil to establish the model of stomatitis mice." | 4.12 | Dual roles of ANGPTL4 in multiple inflammatory responses in stomatitis mice. ( Tian, MM; Wang, YS; Xiao, HB, 2022) |
| "The aim of this study was to analyze the effects of three different Photobiomodulation Therapy (PBMT) protocols in the treatment of 5-fluorouracil-induced oral mucositis in hamsters." | 4.02 | Wound healing process with different photobiomodulation therapy protocols to treat 5-FU-induced oral mucositis in hamsters. ( Arana-Chavez, VE; Calarga, CC; Cotomacio, CC; Simões, A; Yshikawa, BK, 2021) |
| "Glutaryl melatonin exhibited mild anti-candidiasis and anti-inflammatory properties." | 3.96 | Glutaryl Melatonin Niosome Gel for Topical Oral Mucositis: Anti- Inflammatory and Anticandidiasis. ( Daduang, J; Damrongrungruang, T; Mahakunakorn, P; Panpitakkul, P; Panyatip, P; Priprem, A; Puthongking, P; Sangchart, P; Somudorn, J; Uthaiwat, P, 2020) |
| "We used 90 mice of the CF-1 strain in which oral mucositis was induced using a protocol with 5-fluorouracil (5-FU) chemotherapy." | 3.96 | Cannabidiol on 5-FU-induced oral mucositis in mice. ( Borghetti, RL; Cherubini, K; Cuba, LF; de Figueiredo, MAZ; Guimarães, FS; Salum, FG, 2020) |
| "The intent of this article is to evaluate the effect of oral cryotherapy on the prevention of oral mucositis and pain among patients with colorectal cancer undergoing fluorouracil-based chemotherapy." | 3.88 | Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy. ( Hsien Chan, CM; Idayu Mat Nawi, R; Lei Chui, P; Wan Ishak, WZ, 2018) |
| " In this study, we investigated spontaneous pain and mechanical allodynia in a preclinical model of oral ulcerative mucositis after systemic administration of the chemotherapy drug 5-fluorouracil, using our proprietary pain assay system for conscious rats." | 3.83 | Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil. ( Goto, T; Harano, N; Hitomi, S; Inenaga, K; Inoue, H; Ito, M; Matoba, M; Miyano, K; Nodai, T; Ono, K; Uezono, Y; Watanabe, S; Yamaguchi, K, 2016) |
| " We retrospectively examined the progression of oral mucositis in 91 patients with breast cancer who received the 5-fluorouracil, epirubicin, and cyclophosphamide (FEC)-100 regimen between September 2007 and August 2008." | 3.80 | [Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer]. ( Abe, M; Bamba, N; Enami, A; Makihara, K; Masaoka, M; Masuda, N; Mizutani, M; Shikata, A; Takada, S; Yamamoto, M; Yamamura, J; Yasojima, H, 2014) |
| "From June 2007 to July 2008, 61 breast cancer patients eligible for this study received anthracycline-based chemotherapy(FEC100: 5-FU 500mg/m / / 2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)at National Kyushu Cancer Center and Iwate Medical University Hospital." | 3.78 | [High incidence-rate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy (FEC100)]. ( Fukazawa, M; Kashiwaba, K; Kawaguchi, H; Koga, C; Mori, E; Nakamura, Y; Nishimura, S; Ohno, S; Satou, S; Sawamura, K; Shigematsu, H, 2012) |
| "Atorvastatin prevented mucosal damage and inflammation associated with 5-FU-induced OM, but the association of a higher dose of ATV with 5-FU induced hepatotoxicity and amplified leukopenia." | 3.77 | Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis. ( Alencar, NM; Barboza, DR; Brito, GA; Gomes, AS; Leitão, RF; Macedo, RN; Medeiros, CA; Nogueira, NA; Ribeiro, RA, 2011) |
| " The aim of the present report was to evaluate real-life drug adherence in a prospective cohort analysis of patients with gastrointestinal or breast cancer treated with capecitabine-based chemotherapy." | 3.77 | Self-reported compliance with capecitabine: findings from a prospective cohort analysis. ( Bressoud, A; Delmore, G; Hermann, F; Hoesli, P; Pederiva, S; von Moos, R; Winterhalder, R, 2011) |
| " We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients." | 3.72 | FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. ( Autorino, R; Bianco, AR; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M, 2004) |
| "One hundred and three patients with recurrent adenocarcinoma of the rectum underwent reirradiation with concurrent 5-fluorouracil-based chemotherapy." | 3.71 | Long-term results of reirradiation for patients with recurrent rectal carcinoma. ( Marks, G; Marks, J; Mohiuddin, M, 2002) |
| "5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer." | 3.70 | Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998) |
| " Results indicated that the chemotherapy agent 5-fluorouracil (5-FU) administered to hamsters on days 0 and 2 produced severe leukopenia between days 4 and 7 of the trial, and that severity of oral mucositis coincided with the suppressed immune state in these animals." | 3.70 | Evaluation of bovine lactoferrin as a topical therapy for chemotherapy-induced mucositis in the golden Syrian hamster. ( Clarke, J; Edwards, B; Regester, G; Srpek, L, 1999) |
| " Administration of topical TGF-beta 3 prior to chemotherapy with 5-fluorouracil (5-FU) significantly reduced the severity of mucositis with respect to time, reduced chemotherapy-associated weight loss and increased survival." | 3.69 | Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. ( Brien, JP; Bruskin, AM; Haley, JD; Muska, AD; Rose, A; Sonis, ST; Van Vugt, AG, 1997) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 3.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| "In a previous trial in which methotrexate and N-phosphonacetyl-L-aspartate (PALA) were used to modulate 5-fluorouracil (5-FU), four of six patients could not tolerate treatment at the 600 mg/m2 5-FU dose level because of mucositis, diarrhea, and a decrease in performance status." | 3.68 | Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. ( Colofiore, J; Kemeny, N; Martin, D; Sawyer, R; Schneider, A; Seiter, K; Williams, L, 1993) |
| " This prospective cohort study investigated orofacial complications of combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone) in women with breast cancer." | 3.68 | Orofacial complications of chemotherapy for breast cancer. ( McCarthy, GM; Skillings, JR, 1992) |
| "7 mg/kg/d of dipyridamole, we examined the relationships between 5FUra dose and steady-state plasma concentration (Css) and the percentage reduction in WBCs, as well as the percentage frequency of stomatitis." | 3.68 | Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. ( Egorin, MJ; Forrest, A; Remick, S; Trump, DL; Tutsch, KD; Willson, JK, 1991) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | 3.67 | Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| "The authors assessed the value of protracted low-dose 5-fluorouracil (5-FU) infusion (250 mg/m2/day) in refractory breast cancer." | 3.67 | 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. ( Holmes, FA; Hortobagyi, G; Jabboury, K, 1989) |
| "Two hundred and seventy-four consecutive patients with measurable metastatic breast cancer, without prior exposure to cytotoxic agents were treated with tamoxifen, 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC)." | 3.67 | Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. ( Ames, F; Buzdar, AU; Carrasco, CH; Ewer, MS; Fraschini, G; Frye, D; Hortobagyi, GN; Hug, V; Mackay, B; Montague, E, 1989) |
| "Thirty patients with an advanced bronchogenic carcinoma were treated with a combination of adriamycin and 5-fluorouracil; in eight the size of the tumour or its metastases was reduced by over 50%, and eight further patients experienced useful relief of symptoms." | 3.65 | Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil. ( Anderson, G; Bugaighis, A; Rees, GJ, 1975) |
| "The induction of oral mucositis occurred by the administration of intraperitoneal Fluorouracila (60 mg/kg) and trauma to the mucosa." | 3.30 | The chromatographic constitution of andiroba oil and his healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option. ( Alcantara, DDFA; Burbano, RMR; Gomes, JT; Júnior, SMA; Oliveira, CP; Rodrigues, EM; Soares, BM; Soares, RHFC; Tuji, FM; Wanzeler, AMV, 2023) |
| "Oral pain was assessed using a visual analogue scale alongside assessment of patients' perceptions and daily functional activities based on the Rotterdam Symptom Checklist." | 3.30 | Potential therapeutic effects of different mouthwashes for alleviation and treatment of oral complications of 5-fluorouracil-based chemotherapy in patients with colon cancer. ( Al-Taie, A; Koseoglu, A, 2023) |
| "Pentoxifylline (PTX) is a drug that has been shown to have multiple beneficial effects in cancer patients through its anti-inflammatory properties." | 3.01 | Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2021) |
| "To assess S-1 and 5-fluorouracil (5-FU)-related adverse events in patients with advanced gastric cancer and provide focused health care approaches to improve patient compliance and quality of survival." | 3.01 | S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis. ( Chu, T; Hu, Q; Ke, J; Xu, J; Zhang, Z, 2023) |
| "Mucositis is a common and most debilitating complication associated with the cytotoxicity of chemotherapy." | 2.82 | Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models. ( Cirillo, N; Huang, J; Hwang, AYM; Iskandar, M; Jia, Y; Kim, B; Mohammed, AI, 2022) |
| " No difference in other treatment toxicity was observed between the two groups, and patients exhibited high compliance in dosing administration." | 2.80 | Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. ( Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J, 2015) |
| "Patient survival in esophageal cancer (EC) remains poor." | 2.80 | A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer. ( Hayashi, T; Hirakawa, M; Hori, M; Kato, J; Kobune, M; Miyanishi, K; Nakata, K; Ohnuma, H; Okagawa, Y; Osuga, T; Sagawa, T; Sakata, K; Sato, T; Sato, Y; Someya, M; Takayama, T; Takimoto, R, 2015) |
| "Potentiation of oral mucositis was achieved by scratching both cheek pouches of all animals with needles (days 5, 6, and 14)." | 2.78 | Protective effect of bilberry extract as a pretreatment on induced oral mucositis in hamsters. ( Asatourian, A; Davarmanesh, M; Garcia-Godoy, F; Haghnegahdar, S; Miri, R; Saghiri, MA; Tadbir, AA; Tanideh, N, 2013) |
| " The incidence and maximum severity of fluorouracil-induced oral mucositis and safety of the irsogladine dosing regimen were evaluated." | 2.78 | Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis. ( Hayashi, K; Kamata, M; Kojima, H; Nomura, M; Sawada, S, 2013) |
| "Sixty breast cancer patients undergoing an FEC60 regimen were enrolled, 37 patients completed the study." | 2.78 | The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013) |
| "Acute Grade 3 (G3) dysphagia was higher in DL2 (87% DL2 vs." | 2.77 | Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. ( A'hern, R; Barbachano, Y; Bhide, SA; Bidmead, AM; Clark, C; Guerrero-Urbano, MT; Harrington, KJ; Hickey, J; Miah, AB; Newbold, KL; Nicol, R; Nutting, CM; St Rose, S; Tanay, M, 2012) |
| "Deleterious oral mucositis (OM) develops during radiotherapy (RT) or chemoradiotherapy for head-and-neck cancer (HNC) patients." | 2.77 | Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. ( Chung, YL; Jen, YM; Lin, YH; Wang, LW; Yen, SH, 2012) |
| "Gemcitabine was administered intravenously at 1,000 mg/m(2)/week (days 1, 8 and 15) and oral capecitabine from day 1 to day 21 at 1,660 mg/m(2)/day." | 2.77 | Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ( Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H, 2012) |
| "The peak prevalence of grade 3 dysphagia was higher and the recovery was slower in patients with lower OTT (median 38 days vs." | 2.75 | Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. ( Bhide, SA; Fowler, J; Gulliford, S; Harrington, KJ; Newbold, K; Nutting, CM; Rosenfelder, N, 2010) |
| " Patients exhibited high compliance in dosing administration." | 2.74 | Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009) |
| "Forty patients with colorectal cancer were included in this randomized prospective study." | 2.73 | Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer. ( Aydiner, A; Aykan, F; Can, G; Cevikbaş, A; Cinar, S; Deniz, G; Derin, D; Dişçi, R; Durna, Z; Guney, N; Gürer, U; Kürklü, E; Saglam, S; Sakar, B; Tanyeri, H; Taş, F; Topuz, E, 2008) |
| "Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter." | 2.73 | A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. ( Adimi, P; Andersen, LJ; Bastholt, L; Larsen, S; Lindeløv, B; McCulloch, T; Serup-Hansen, E, 2007) |
| " The most frequent common adverse events were nausea, Grades 1 - 2 in 13 patients (81." | 2.72 | Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. ( Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Wedding, U, 2006) |
| "Thirty-two patients with head-and-neck cancer were treated with chemoradiotherapy (CRT) (radiotherapy daily up to 70 Gy plus cisplatin/5-fluoruracil once a week) and were asked to participate." | 2.72 | Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. ( Bonomi, M; Cabalar, ME; Castro, MA; Cerchietti, LC; Kirchuk, R; Lutteral, MA; Navigante, AH; Negretti, G; Roth, B; Sheinker, B; Uchima, P, 2006) |
| "Preoperative chemoradiotherapy in rectal cancer using chronomodulated 5-FU and LV is feasible." | 2.71 | Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer. ( Berry, S; Bjarnason, GA; Davey, P; de Marsh, RW; Mendenhall, W; Parulekar, W; Rout, WR; Wong, R; Zlotecki, R, 2004) |
| "Capecitabine was given twice daily, 7 days a week at a dose starting at 350 mg/m(2) bid." | 2.71 | Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. ( Ironside, JA; MacDougall, RH; Mais, KL; Slevin, NJ; Sykes, AJ, 2004) |
| "Oral mucositis is a frequent and potentially severe complication of radiation or chemotherapy for cancer." | 2.71 | Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies. ( Aksungur, P; Iskit, AB; Senel, S; Squier, CA; Sungur, A; Unal, S, 2004) |
| "Capecitabine was administered orally on day 1 of radiotherapy by an intermittent schedule (14 days treatment; 7-day rest) at 3 weekly intervals for two cycles." | 2.71 | [Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma]. ( Guo, L; Guo, X; Hong, MH; Li, FY; Li, Q; Lin, HX; Luo, DH; Qiu, F, 2004) |
| "Capecitabine was administered in twice daily divided doses, and CI-994 was given as a single daily dose." | 2.71 | A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. ( Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ, 2004) |
| "Oral mucositis was assessed by nurses prior to each of the three chemotherapy cycles and 15 days after each intervention." | 2.71 | Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. ( Hyde, S; Kristjanson, LJ; Myers, H; Nikoletti, S; Shaw, T, 2005) |
| " This regimen is under way in which chemotherapy with 5-FU 500 mg/day on days 1 to 5 and superselective intra-arterial infusion of CDGP on day 6 combined with radiation therapy is being evaluated for locally advanced oral cancer." | 2.71 | [Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer]. ( Goto, M; Shikimori, M; Yamshita, Y, 2005) |
| " We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma." | 2.70 | Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002) |
| "The mean size of lesions of oral mucositis was 1." | 2.70 | Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Steger, GG; Wiltschke, C; Zielinski, CC, 2001) |
| "Capecitabine is a novel fluoropyrimidine carbamate, orally administered and selectively activated to fluorouracil by a sequential triple-enzyme pathway in liver and tumor cells." | 2.70 | Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. ( Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC, 2002) |
| "Gemcitabine was administered as a 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break." | 2.70 | Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. ( Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 2002) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 2.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "Twenty-three patients with advanced head and neck cancer, mainly Stage III and IV, were treated with preoperative radiation (n = 1), pre- as well as postoperative radiotherapy (n = 5), postoperative radiation (n = 9) or combined postoperative radio-chemotherapy (n = 6)." | 2.69 | [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. ( Altmann, S; Hoffmanns, H, 1999) |
| "Oral mucositis is a frequent side effect of cancer therapy." | 2.68 | A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. ( Burkhead, T; Garewal, HS; Koenig, LM; Vaughn, B; Verdi, CJ, 1995) |
| "Twenty patients with stage IV squamous cell carcinoma of head and neck were studied." | 2.68 | Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. ( Chan, WK; Chang, CY; Chao, JY; Chen, CH; Chen, KY; Chen, SY; Chi, KH; Chow, KC; Yen, SH, 1995) |
| "Stomatitis was seen more in arm B and C than in arm A." | 2.68 | [A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group]. ( Akazawa, S; Konishi, T; Kumai, K; Kurihara, M; Ogawa, M; Ogawa, N; Ota, K; Sasaki, T; Taguchi, T; Tominaga, T, 1995) |
| " Patients who received Tomudex spent a substantially shorter time in hospital for dosing and had significantly lower rates of grade 3 and 4 toxicities such as leucopenia and mucositis." | 2.68 | 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. ( Cunningham, D; Harper, P; Kerr, D; Olver, I; Perez-Manga, G; Rath, U; Seitz, JF; Svensson, C; Van Cutsem, E; Zalcberg, JR, 1995) |
| "Thirty-two patients (76%) had no oral mucositis." | 2.68 | Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. ( Chan, WK; Chen, KY; Chen, SY; Chi, KH; Law, CK; Shu, CH; Yen, SH, 1995) |
| "Mucositis is a common toxicity of cancer chemotherapy." | 2.68 | Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. ( Anderson, PM; Skubitz, KM, 1996) |
| "Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin." | 2.68 | Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. ( Buckner, JC; Cascino, TL; Goldberg, RM; Kuross, SA; Levitt, R; Morton, RF; O'Fallon, JR; Scheithauer, BW; Veeder, MH; Wiesenfeld, M, 1996) |
| "Levamisole was administered orally (days 1-3 and 15-17) at doses from 30 to 470 mg/m2 per day." | 2.68 | A phase I study of 5-fluorouracil, leucovorin and levamisole. ( Alberti, D; Arzoomanian, R; Carbone, P; Cleary, JF; Feierabend, C; Storer, B; Wilding, G; Witt, P, 1997) |
| "Twelve patients with locally advanced breast carcinoma received HD-CT followed by peripheral stem cell reinfusion." | 2.68 | A new in vitro assay for quantitation of chemotherapy-induced mucositis. ( de Vries, EG; Mulder, NH; Sluiter, WJ; Spijkervet, FL; Timens, W; Timmer-Bosscha, H; van der Graaf, WT; Wymenga, AN, 1997) |
| "Grade 3-4 toxicities included oral mucositis in 19 patients, granulocytopenia in 16, fatigue in 8, and diarrhea in 3." | 2.67 | Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. ( Abbruzzese, JL; Ajani, JJ; Belt, RJ; Dakhil, SR; Dubovsky, D; Graham, S; Levin, B; Pazdur, R; Pilat, S; Winn, R, 1992) |
| "Stomatitis was observed in 44/78 (56%) courses." | 2.67 | A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. ( Alberti, D; Arzoomanian, RZ; Bailey, H; Grem, JL; Spriggs, DR; Tombes, MB; Tutsch, KD; Wilding, G, 1992) |
| "Oral hydroxyurea (HU) was added to a regimen of 5-fluorouracil (5-FU) plus leucovorin (LCV) administered as a continuous 24-hour infusion for 14 days." | 2.67 | Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial. ( Anderson, N; Bern, M; Coco, F; Gonsalves, L; Lokich, J; Moore, C; Zipoli, T, 1991) |
| "5-Fluorouracil was infused 24 hours per day throughout the period of radiation at a dose of 300 mg/m2/day for a median of 42 days (range, 28-56 days)." | 2.66 | Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer. ( Chaffey, J; Lokich, J; Neptune, W, 1989) |
| "Stomatitis was more frequent on the infusion arm but it was mild and reversible." | 2.66 | A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. ( Al-Sarraf, M; Cummings, G; Ensley, JF; Jacobs, J; Kish, JA; Weaver, A, 1985) |
| "Ulcerative oral mucositis can be costly to healthcare systems, yet there are few preventive interventions proven to be beneficial." | 2.52 | Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. ( Clarkson, JE; Glenny, AM; Littlewood, A; McCabe, MG; Riley, P; Worthington, HV, 2015) |
| "Adjuvant therapy for colorectal cancer has been one of the most important contributions of medical oncology to the health of the population, saving more lives annually than more effective therapy for less common cancers, such as Hodgkin's disease." | 2.42 | Adjuvant therapy for rectal cancer in the elderly. ( Cohen, SM; Neugut, AI, 2004) |
| " Hand-foot syndrome (HFS) is the only clinical adverse event occurring more often during capecitabine treatment." | 2.42 | Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). ( Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E, 2004) |
| "Capecitabine has a favourable safety profile, the most frequent adverse events being hand-foot syndrome, stomatitis and diarrhoea." | 2.42 | Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. ( Holland, M; Reichardt, P; Sternberg, CN, 2004) |
| "Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells." | 2.41 | Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002) |
| "Oral mucositis is a frequent and potentially severe complication of chemotherapy which has a considerable impact on patient quality of life." | 2.41 | Chemotherapy-induced oral mucositis. Prevention and management. ( Feld, R; Knox, JJ; Puodziunas, AL, 2000) |
| "Pursuant to this, the North Central Cancer Treatment Group has developed a series of clinical trials designed to study antidotes for these pathologic processes." | 2.39 | Alleviation of cytotoxic therapy-induced normal tissue damage. ( Foote, RL; Loprinzi, CL; Michalak, J, 1995) |
| "Chemotherapy-induced oral mucositis (COM) is a common adverse effect of cancer chemotherapy." | 1.91 | Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis. ( Hira, D; Imai, S; Ito, M; Itohara, K; Kagawa, M; Matsubara, K; Nakagawa, S; Nakagawa, T; Ogihara, T; Terada, T; Yamanaka, R; Yonezawa, A, 2023) |
| "The current idea of how oral mucositis (OM) develops is primarily based on hypotheses and the early events which precede clinically established OM remain to be demonstrated." | 1.91 | Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats. ( Aydogdu, Ö; Dankis, M; Jontell, M; Walladbegi, J; Winder, M, 2023) |
| "Oral and intestinal mucositis are debilitating inflammatory diseases observed in cancer patients undergoing chemo-radiotherapy." | 1.91 | Characterization of a novel dual murine model of chemotherapy-induced oral and intestinal mucositis. ( Celentano, A; Cirillo, N; Low, JT; McCullough, MJ; Mohammed, AI; O' Reilly, LA; Paolini, R, 2023) |
| "However, the β-cry effect on oral mucositis remains unclear." | 1.91 | Anti-Inflammatory Effects of β-Cryptoxanthin on 5-Fluorouracil-Induced Cytokine Expression in Human Oral Mucosal Keratinocytes. ( Kanamura, N; Kishimoto, S; Mazda, O; Nakai, K; Oseko, F; Yamamoto, K; Yamamoto, T; Yamanobe, H, 2023) |
| "5-Fluorouracil (5-FU)-induced oral mucositis has a severe negative impact on the patient's quality of life." | 1.72 | Protective effect of endoplasmic reticulum stress inhibition on 5-fluorouracil-induced oral mucositis. ( Cao, YN; Chen, C; Hou, Y; Li, M; Shan, E; Shan, J; Wang, J; Wang, Y; Zhang, L; Zhou, Y, 2022) |
| "Metformin (Met) is a first-line and essential treatment for type 2 diabetes, with anti-inflammatory effects." | 1.72 | Metformin protects 5-Fu-induced chemotherapy oral mucositis by reducing endoplasmic reticulum stress in mice. ( Chen, Y; Li, X; Ma, R; Shan, E; Shan, J; Sun, H; Zhang, J; Zhou, Y, 2022) |
| "Changes in body weight and white blood cell count were measured to determine the optimal dosing schedule." | 1.62 | Therapeutic Effects of GGsTop ( Makino, K; Takeuchi, I; Tanaka, K, 2021) |
| "Due to the worsening of oral mucositis, the patient may progress to a worse clinical condition and interrupt antineoplastic treatment." | 1.62 | Laser Therapy as a Preventive Approach for Oral Mucositis in Cancer Patients Undergoing Chemotherapy: The Potential Role of Superoxide Dismutase. ( Bissoli, NS; Bonela, LAS; Gonçalves, WL; Gouvea, SA; Menezes, BC; Oliveira, KG; Sartorio, CL; Thebit, MM, 2021) |
| "Oral mucositis was induced in ICR mice by 5-FU and randomly assigned to receive daily applications of the topical oral MNG, a fluocinolone acetonide gel, a blank niosome gel, or no treatment for 5 days in comparison with a normal group." | 1.62 | Topical Melatonin Niosome Gel for the Treatment of 5-FU-Induced Oral Mucositis in Mice. ( Boonsiri, P; Chio-Srichan, S; Daduang, J; Lee, YC; Mahakunakorn, P; Priprem, A; Settasatian, C; Uthaiwat, P, 2021) |
| " Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation." | 1.62 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021) |
| "A chemoradiation-induced oral mucositis model was established by treating mice with concurrent 5-fluorouracil (100 mg/kg, i." | 1.56 | 1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol ameliorates chemoradiation-induced oral mucositis. ( Choi, S; Kim, JW; Lee, HR; Shin, SH; Sohn, KY; Yoon, SY, 2020) |
| "Oral mucositis was induced in hamsters by administration of 5-fluorouracil (day 0, 2, 4) followed by mechanical trauma (day 1, 2, 4)." | 1.56 | Wound Healing Promoting Activity of Tonsil-Derived Stem Cells on 5-Fluorouracil-Induced Oral Mucositis Model. ( Jung, H; Kim, HS; Lee, JH; Lee, JJ; Park, HS, 2020) |
| "A model animal of oral mucositis was prepared by injecting an acetic acid aqueous solution into the buccal mucosa of rats to which a 5-FU solution had been previously administered." | 1.56 | A Rat Model of Oral Mucositis Induced by Cancer Chemotherapy for Quantitative Experiments. ( Kawamata, R; Makino, K; Takeuchi, I, 2020) |
| "Oral mucositis is a common inflammatory complication among patients with cancer." | 1.56 | Effect of Topical 2% Eucalyptus Extract on 5-FU-Induced Oral Mucositis in Male Golden Hamsters. ( Andisheh-Tadbir, A; Badie, A; Habibagahi, R; Haghnegahdar, S; Koohi-Hosseinabadi, O; Tanideh, N, 2020) |
| "Oral mucositis (OM) induced by cancer chemotherapy has a high incidence and serious symptoms, which often force chemotherapy to be stopped." | 1.51 | Therapeutic Effect of GGsTop, Selective Gamma-glutamyl Transpeptidase Inhibitor, on a Mouse Model of 5-Fluorouracil-induced Oral Mucositis. ( Makino, K; Shimamura, Y; Takeuchi, I; Terada, H, 2019) |
| "Oral mucositis is an important adverse effect of chemotherapy, and its severity, frequency, and impact on patient quality of life should not be underestimated." | 1.51 | Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer. ( Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Tajima, H; Takamura, H; Terai, S; Yamaguchi, T, 2019) |
| "extract on oral mucositis (OM) induced by 5-fluorouracil (5-FU) in hamsters." | 1.51 | Mucoadhesive formulation containing Curcuma longa L. reduces oral mucositis induced by 5-fluorouracil in hamsters. ( Batista, AC; Curra, M; de Oliveira, AC; Marreto, RN; Martins, MAT; Martins, MD; Schmidt, TR; Valadares, MC; Wagner, VP, 2019) |
| "Elental reduced oral mucositis and dermatitis more effectively than dextrin in the animal model." | 1.48 | Elemental Diet Accelerates the Recovery From Oral Mucositis and Dermatitis Induced by 5-Fluorouracil Through the Induction of Fibroblast Growth Factor 2. ( Ferdous, T; Harada, K; Kobayashi, H; Ueyama, Y, 2018) |
| "Oral mucositis is a side effect of treatment regimens containing 5-fluorouracil (5-FU)." | 1.48 | Peroxisome proliferator activated receptor-gamma stimulation for prevention of 5-fluorouracil-induced oral mucositis in mice. ( Biti, G; Bonomo, P; Castiglione, F; Desideri, I; Francolini, G; Gerini, C; Grassi, R; Greto, D; Livi, L; Loi, M; Mangoni, M; Meattini, I; Perna, M; Salvatore, G; Sottili, M, 2018) |
| "Oral mucositis is a common side effect of cancer chemotherapy, with significant adverse impact on the delivery of anti-neoplastic treatment." | 1.48 | Chemotherapy-induced oral mucositis and associated infections in a novel organotypic model. ( Bertolini, M; Diaz, PI; Dongari-Bagtzoglou, A; Peterson, DE; Sobue, T; Thompson, A, 2018) |
| "The cytotoxic effect of chemotherapeutic agents to the oral mucosa, as a side effect of cancer treatment, is a major problem." | 1.48 | Cooling of the oral mucosa to prevent adverse effects of chemotherapeutic agents: An in vitro study. ( Colley, HE; Grayson, AK; Jontell, M; Murdoch, C; Smith, SA; Walladbegi, J, 2018) |
| "Oral mucositis is one of the most common side effects induced by cancer therapy, and the prevention or rapid treatment of the symptoms of oral mucositis can improve patients' quality of life and reduce the need for treatment interruption." | 1.48 | Therapeutic efficacy of rebamipide-loaded PLGA nanoparticles coated with chitosan in a mouse model for oral mucositis induced by cancer chemotherapy. ( Kamiki, Y; Makino, K; Takeuchi, I, 2018) |
| "Oral mucositis was induced in hamsters with 5-fluorouracil (5-FU; 60 mg/kg day 1 and 40 mg/kg day 2)." | 1.48 | Protective effect of angiotensin II receptor blocker against oxidative stress and inflammation in an oral mucositis experimental model. ( Araújo Junior, RF; Araújo, AA; Araújo, LS; Brito, GAC; Costa, DVDS; Garcia, VB; Guerra, GCB; Leitão, RFC; Lima, MLS; Medeiros, CACX, 2018) |
| "Chemotherapy-induced oral mucositis impairs the quality of life." | 1.48 | Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study. ( Dote, S; Hira, D; Itakura, S; Kamei, K; Kobayashi, Y; Noda, S; Terada, T, 2018) |
| " The frequency and severity of these adverse events vary from patient to patient and are partially explained by genetic polymorphism into the dihydropyrimidine dehydrogenase (DPYD) gene." | 1.46 | Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms. ( Cergnul, M; Cheli, S; Falvella, FS; Fava, S; Luoni, M, 2017) |
| "Oral mucositis was induced in hamsters using 5-fluorouracil (5-FU; 60 and 40 mg/kg; i." | 1.46 | Role of the route of leukotrienes in an experimental model of oral mucositis induced by 5-fluorouracil 1. ( Aragão, KS; Brito, GAC; Freire, GE; Freitas, MR; Leitão, RFC; Martins, CDS; Silva, VCD; Wanderley, CWS, 2017) |
| "Apigenin treatment may enhance healing of OM induced by 5-fluorouracil, thus suggesting that more extensive research in this area may be useful to assess the role of agents of natural origin capable of preventing OM." | 1.46 | The therapeutic effects of apigenin and dexamethasone on 5-fluorouracil-induced oral mucositis - a pilot study using a Syrian hamster model. ( Amaral Mendes, R; Gómez Garcia, F; Lopez-Jornet, P; Martinez Diaz, F; Molina Prats, P, 2017) |
| "Forty hamsters with oral mucositis induced by 5-fluorouracil administered on days 0, 5 and 10 and buccal mucosal scratching were randomly divided into four equal groups: group 1 received no additional treatment, group 2 received gel base, and groups 3 and 4 received gels containing 5% and 10% oil, respectively." | 1.46 | Healing acceleration of oral mucositis induced by 5-fluorouracil with Pistacia atlantica (bene) essential oil in hamsters. ( Andisheh-Tadbir, A; Davarmanesh, M; Koohi-Hosseinabadi, O; Mehriar, P; Ranjbar, Z; Tanideh, N, 2017) |
| "Twenty esophageal cancer patients receiving chemotherapy with 5-fluorouracil plus cisplatin were assigned randomly to one of the following two groups: (1) receiving elemental diet with Elental (one pack per day) for 14 days and (2) not receiving Elental during chemotherapy." | 1.46 | A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Okada, T; Ryotokuji, T; Tokairin, Y, 2017) |
| "Oral mucositis was induced through a combination of 5-FU treatment and mild abrasion of the cheek pouch with a wire brush." | 1.43 | Effect of a corticosteroid (triamcinolone) and chlorhexidine on chemotherapy-induced oxidative stress in the buccal mucosa of rats. ( Aynali, G; Başpınar, Ş; Gümüş, S; Nazıroğlu, M; Uğuz, AC; Yarıktaş, M, 2016) |
| "Chemotherapy-induced oral mucositis is a common adverse event in patients with oral squamous cell carcinoma, and is initiated through a variety of mechanisms, including the generation of reactive oxygen species (ROS)." | 1.42 | γ-Tocotrienol prevents 5-FU-induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5-FU-induced activation of Nrf2. ( Aota, K; Azuma, M; Kani, K; Momota, Y; Takano, H; Yamamura, Y; Yamanoi, T, 2015) |
| "Oral mucositis is a reaction to chemoradiation therapy during cancer treatment." | 1.42 | Amniotic membrane as a biological dressing for 5-fluoruracil-induced oral mucositis in rats. ( Carvalho, MA; Gomes, MF; Lima, Gde M; Salgado, MA; Santana-Melo, Gde F; Severo, MC; Vilela-Goulart, Md, 2015) |
| " Severe toxic reactions to 5-FU have been associated with decreased levels of dihydropyrimidine dehydrogenase (DPD) enzyme activity." | 1.40 | A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. ( Diasio, RB; Lee, AM; McConnell, K; Offer, SM; Relias, V; Saif, MW, 2014) |
| "The recovery stage of oral mucositis was evaluated through daily weighing, measurements of the ulcer area, histopathologic analysis, and a myeloperoxidase activity assay." | 1.40 | Platelet-rich fibrin has a healing effect on chemotherapy-induced mucositis in hamsters. ( Horii, K; Kanayama, T; Kohgo, T; Miyamoto, H; Shigetomi, T; Tsuchimochi, T; Yokoi, M, 2014) |
| "perforatum extract on oral mucositis." | 1.40 | Comparative assessment of the therapeutic effects of the topical and systemic forms of Hypericum perforatum extract on induced oral mucositis in golden hamsters. ( Andisheh Tadbir, A; Ebrahimi, H; Koohi-Hosseinabadi, O; Namazi, F; Tanideh, N, 2014) |
| "Oral mucositis was induced in male hamsters by two intraperitoneal administrations of 5-FU on the first and second days of the experiment (60 and 40 mg/kg, respectively) followed by mechanical trauma on the fourth day." | 1.40 | S-nitrosoglutathione accelerates recovery from 5-fluorouracil-induced oral mucositis. ( Baldim, V; Braga, CM; Brito, GA; Cavalcante, MM; Colombo, AP; de Oliveira, MG; Holanda-Afonso, RC; Leitão, RF; Moura-Neto, V; Ribeiro, RA; Silva-Boghossian, CM; Skeff, MA, 2014) |
| "Oral mucositis was induced in Syrian hamster cheek pouches by 5-fluorouracil treatment and mechanical scratching." | 1.39 | Effect of rice cell-derived human granulocyte-macrophage colony-stimulating factor on 5-fluorouracil-induced mucositis in hamsters. ( Ahn, KH; Choi, JM; Ha, HC; Han, K; Ji, JE; Kim, DK; Kim, HM; Kim, SK; Won, JH; Yun, CK, 2013) |
| "It has been reported that oral mucositis can reduce quality of life, as well as increasing the incidence of mortality." | 1.39 | Alteration of the redox state with reactive oxygen species for 5-fluorouracil-induced oral mucositis in hamsters. ( Lee, MC; Nakajima, A; Takahashi, SS; Wada-Takahashi, S; Yoshida, A; Yoshino, F, 2013) |
| "Weight gain was noted in the treatment groups compared with the gel base and control groups (P < ." | 1.39 | Healing acceleration in hamsters of oral mucositis induced by 5-fluorouracil with topical Calendula officinalis. ( Amanat, D; Garcia-Godoy, F; Saghiri, MA; Samani, SM; Tadbir, AA; Tamadon, A; Tanideh, N; Tavakoli, P, 2013) |
| "Oral mucositis was induced in hamsters through a combination of 5-FU treatment and mild abrasion of the cheek pouch." | 1.39 | Oral mucosal adhesive films containing royal jelly accelerate recovery from 5-fluorouracil-induced oral mucositis. ( Araki, H; Imai, K; Kaji, H; Suemaru, K; Takechi, K; Watanabe, S, 2013) |
| "Population-based studies of adverse events are scarce." | 1.38 | Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. ( Cen, P; Du, XL; Liu, C, 2012) |
| "Oral mucositis is an important dose-limiting and costly side effect of cancer chemotherapy." | 1.38 | Protein fraction of Calotropis procera latex protects against 5-fluorouracil-induced oral mucositis associated with downregulation of pivotal pro-inflammatory mediators. ( Bitencourt, FS; Brito, GA; de Alencar, NM; Freitas, AP; Lima-Júnior, RC; Ramos, MV; Ribeiro, RA; Vale, ML, 2012) |
| "Chamomile proved effective in the treatment of oral mucositis in a hamster model." | 1.37 | Healing action of topical chamomile on 5-fluoracil induced oral mucositis in hamster. ( Bussadori, SK; Fernandes, KP; Lopez, TC; Martins, MA; Martins, MD; Mesquita-Ferrari, RA; Pavesi, VC; Sant'Ana Filho, M, 2011) |
| "World Health Organization scores for oral mucositis were documented weekly and correlated with DSB repair." | 1.37 | The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer. ( Derschang, S; Fleckenstein, J; Fricke, A; Gräber, S; Kühne, M; Melchior, P; Rübe, C; Rübe, CE; Seegmüller, K, 2011) |
| "Three patients (20%) had grade 3-4 dysphagia in weeks 3-4 and were continued on intravenous fluids and pain medications." | 1.37 | Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. ( Ad, VB; Bar-Ad, V; Both, S; Hwang, WT; Metz, J; O'Dwyer, P; Plastaras, J; Thukral, A, 2011) |
| "Strictures were associated with tumor location (tonsil vs base of tongue; p = ." | 1.37 | Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. ( Best, SR; Blanco, RG; Califano, JA; Ha, PK; Levine, MA; Messing, BP; Murakami, P; Pai, SI; Saunders, JR; Thompson, R; Trachta, J; Ulmer, K; Walker, M; Zinreich, ES, 2011) |
| "Stomatitis is a side effect caused frequently by chemotherapy in patients with esophageal cancer, but a standard treatment for it has not been established." | 1.37 | [Elental prevented and reduced oral mucositis during chemotherapy in patients esophageal cancer]. ( Fukui, T; Itoh, Y; Kawada, S; Orihara, M; Takeda, H; Yoshioka, T; Yoshizawa, K, 2011) |
| "A hamster cheek pouch model of oral mucositis was used with all animals receiving intraperitoneal 5-fluorouracil, followed by surface irritation." | 1.36 | Effects of low-level laser therapy on collagen expression and neutrophil infiltrate in 5-fluorouracil-induced oral mucositis in hamsters. ( Alves, MT; Chavantes, MC; da Silva, MA; Lalla, RV; Lopes, NN; Plapler, H; Yoshimura, EM, 2010) |
| "Oral mucositis was induced in hamsters through a combination of 5-fluorouracil and mild abrasions that were made on the cheek pouch." | 1.35 | Topical application of royal jelly has a healing effect for 5-fluorouracil-induced experimental oral mucositis in hamsters. ( Araki, H; Cui, R; Hashimoto, K; Li, B; Okihara, K; Suemaru, K; Watanabe, S; Yamada, H, 2008) |
| "Oral mucositis is a frequent and significant side effect of chemotherapy and/or radiation therapy." | 1.35 | Homogenous amniotic membrane as a biological dressing for oral mucositis in rats: histomorphometric analysis. ( Gomes, MF; Niccoli-Filho, W; Rangel, DC; Teixeira, RT; Vilela-Goulart, Md, 2008) |
| "A hamster cheek pouch model of oral mucositis was used with all animals receiving intraperitoneal 5-fluorouracil followed by surface irritation." | 1.35 | Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols. ( Alves, MT; Chavantes, MC; Lalla, RV; Lopes, NN; Plapler, H; Yoshimura, EM, 2009) |
| "We focused on the relationship between oral mucositis and keratinocyte injury and examined methotrexate and 5-fluorouracil-induced cytotoxicity in normal human epidermal keratinocyte cell lines." | 1.35 | Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal keratinocyte toxicity induced by methotrexate and 5-fluorouracil. ( Kaji, H; Maiguma, T; Makino, K; Teshima, D, 2009) |
| "Oral mucositis was induced in hamsters through a combination of 5-FU treatment and mild abrasion of the cheek pouch." | 1.35 | Effect of oral mucosal adhesive films containing ginsenoside Rb1 on 5-fluorouracil-induced oral mucositis in hamsters. ( Araki, H; Hidaka, N; Sakanaka, M; Suemaru, K; Watanabe, S; Yamaguchi, T, 2009) |
| "The 5-FU-induced oral mucositis significantly decreased the serum glutamine levels as well as the cheek pouch glutathione stores observed on day 10." | 1.35 | Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster. ( Bellaguarda, EA; Brito, GA; Leitão, RF; Lira, AM; Macedo, FD; Ribeiro, RA; Silva, LR; Sousa, RB, 2008) |
| "Oral mucositis was induced by two intraperitoneal (i." | 1.34 | Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. ( Bellaguarda, EA; Brito, GA; Cunha, FQ; Leitão, RF; Macedo, FD; Oriá, RB; Ribeiro, RA; Silva, LR; Vale, ML, 2007) |
| " In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen." | 1.34 | [The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| "Oral mucositis is a frequent side-effect of cancer therapy." | 1.33 | Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. ( Augusto, RF; Brito, GA; Cunha, FQ; Falcão, BA; Leitão, BT; Lima, V; Rebouças, CG; Ribeiro, RA; Souza, ML, 2005) |
| "Oral mucositis was induced in hamsters through a combination treatment of 5-fluorouracil and mild abrasion of the cheek pouch." | 1.33 | Evaluation of topical external medicine for 5-fluorouracil-induced oral mucositis in hamsters. ( Araki, H; Cui, R; Li, B; Mitsuhashi, H; Suemaru, K, 2006) |
| "Oral mucositis is a common, treatment-limiting, and costly side effect of cancer treatments whose biological underpinnings remain poorly understood." | 1.32 | An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters. ( Baroukh, B; Barritault, D; Caruelle, JP; Godeau, G; Ledoux, D; Morvan, FO; Saffar, JL, 2004) |
| "Twenty patients with advanced gastric cancer received biweekly regimen of CF/5-FU/PTX (200 mg/m(2) of CF, intravenous infusion for 2 h, day 1; 500 mg/m(2) of 5-FU, intravenous injection, day 1; 1 500 mg/m(2) of 5-FU, intravenous infusion for 46 h, day 1, 2; 90 mg/m(2) of PTX, intravenous infusion for 3 h,day 1)." | 1.32 | [Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer]. ( Feng, JF; Lu, JW; Sun, XF, 2004) |
| "Oral mucositis was induced in Syrian golden hamsters through a combination treatment of the antimetabolite chemotherapy drug 5-fluorouracil (5-FU), and mild abrasion of the cheek pouch." | 1.31 | Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. ( Butler, R; Clarke, J; Howarth, G; Read, L; Regester, G, 2002) |
| "Improvement of oral mucositis was associated with a significant decrease of intestinal permeability to lactulose." | 1.31 | Intestinal permeability in patients with chemotherapy-induced stomatitis. ( Brátová, M; Kohout, P; Králícková, P; Melichar, B; Solichová, D; Zadák, Z, 2001) |
| "All of them had stage IV, unresectable squamous cell carcinoma of the pharynx and they received continuous bid radiotherapy (two daily fractions of 1." | 1.31 | [Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]. ( Bensadoun, RJ; Chauvel, P; Courdi, A; Dassonville, O; Demard, F; Ettore, F; Falewee, MN; Lagrange, JL; Magné, N; Marcy, PY; Milano, G; Pivot, X; Poissonnet, G; Santini, J; Schneider, M; Vallicioni, J, 2001) |
| "Deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-fluorouracil (5-FU) catabolism, has been linked to toxic side effects of 5-FU." | 1.31 | Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. ( Behnke, D; Häusler, P; Höffken, K; Raida, M; Schwabe, W; Van Gennip, AH; Van Kuilenburg, AB, 2001) |
| "Oral mucositis is a dose-limiting toxicity of 5-fluorouracil (5-FU)." | 1.30 | Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. ( Awde, JD; Ghandi, H; Kocha, WI; McCarthy, GM; Vincent, M, 1998) |
| "Oral mucositis was induced in hamsters by intraperitoneal injection of 5-fluorouracil followed by superficial abrasion of the buccal mucosa." | 1.30 | Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. ( Embree, JR; Fiddes, JC; Loury, D; Sonis, ST; Steinberg, DA, 1999) |
| "Patients with head and neck cancer who chewed betel quid habitually seem to experience more severe chemotherapy-induced mucositis in our clinical practice." | 1.30 | Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent. ( Chen, IH; Chen, JS; Liao, CT; Su, CL; Wang, CH; Wang, HM, 1999) |
| "Oral mucositis was induced in male Golden Syrian hamsters with 5-fluorouracil 60 mg/kg intraperitoneal, days 0 and 2." | 1.29 | IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. ( Albert, L; Keith, JC; Pfeiffer, CJ; Schaub, RG; Sonis, ST, 1994) |
| "Hydroxyurea is an active single agent in squamous cell cancer of the head and neck." | 1.28 | Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; Panje, WR; Schilsky, RL; Vokes, EE; Weichselbaum, RR, 1992) |
| "However, stomatitis is one of the limiting side effects." | 1.28 | Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes. ( Elzawawy, A, 1991) |
| "Oral mucositis is a major toxic effect related to 5-fluorouracil (5-FU) therapy." | 1.28 | Studies on the prevention of 5-fluorouracil-induced oral mucositis. ( Dose, AM; Loprinzi, CL, 1990) |
| " Thus, TMTX can be given with 5-FU (400 mg/m2) on a daily x 5-day bolus schedule at the 12 mg/m2 per day dose level, which was the recommended dose of TMTX as a single agent for phase II studies using the 5-day bolus schedule." | 1.28 | Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ( Catalano, R; Comis, RL; DeLap, RJ; Grillo-Lopez, AJ; Hudes, GR; LaCreta, F, 1989) |
| "Thirty-six patients with advanced colorectal cancer with unequivocal evidence of progression while treated with fluoropyrimidines were treated with a six-day continuous infusion of 500 mg/m2/d of folinic acid initiated 24 hours before a five-day course of 5-FU administered as an intravenous (IV) bolus of 370 mg/m2/d." | 1.27 | High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. ( Bertrand, M; Blayney, DW; Carr, BI; Cecchi, G; Doroshow, JH; Goldberg, D; Leong, L; Margolin, K; Metter, G; Multhauf, P, 1986) |
| "We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days." | 1.27 | High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. ( Astone, A; Barone, C; Cassano, A; Cavallaro, A; Garufi, C; Grieco, A; Netri, G; Noviello, MR; Ricevuto, E; Rossi, S, 1987) |
| "Allopurinol has been shown to decrease the gastro-intestinal and bone marrow toxicity of 5-fluorouracil." | 1.27 | Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. ( Clark, PI; Slevin, ML, 1985) |
| "Thirty patients with squamous cell carcinoma of the head and neck were treated with a combination of cisplatin (20 mg/m2) and 5-FU (400-200 mg/m2) by iv push on Days 1-5 every 21 days." | 1.27 | Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule. ( Grimaldi, A; Margarino, G; Merlano, M; Rosso, R; Tatarek, R, 1985) |
| "Stomatitis was the predominant dose-limiting toxicity (22% grade 1, 19% grade 2, and 27% grade 3 toxicity)." | 1.26 | Allopurinol modulation of fluorouracil toxicity. ( Fox, RM; Piper, AA; Sampson, D; Tattersall, MH; Woods, RL, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 54 (14.56) | 18.7374 |
| 1990's | 84 (22.64) | 18.2507 |
| 2000's | 92 (24.80) | 29.6817 |
| 2010's | 104 (28.03) | 24.3611 |
| 2020's | 37 (9.97) | 2.80 |
| Authors | Studies |
|---|---|
| Takeuchi, I | 5 |
| Tanaka, K | 1 |
| Makino, K | 6 |
| Cotomacio, CC | 2 |
| Calarga, CC | 1 |
| Yshikawa, BK | 1 |
| Arana-Chavez, VE | 3 |
| Simões, A | 3 |
| Menezes, BC | 1 |
| Thebit, MM | 1 |
| Bonela, LAS | 1 |
| Oliveira, KG | 1 |
| Gonçalves, WL | 1 |
| Bissoli, NS | 1 |
| Sartorio, CL | 1 |
| Gouvea, SA | 1 |
| Severo, MLB | 1 |
| Thieme, S | 1 |
| Silveira, FM | 1 |
| Tavares, RPM | 1 |
| Gonzaga, AKG | 1 |
| Zucolotto, SM | 1 |
| de Araújo, AA | 2 |
| Martins, MAT | 2 |
| Martins, MD | 6 |
| da Silveira, ÉJD | 2 |
| Meirovitz, A | 1 |
| Baider, L | 1 |
| Peretz, T | 1 |
| Stephanos, S | 1 |
| Barak, V | 1 |
| Cao, YN | 1 |
| Wang, Y | 3 |
| Zhang, L | 2 |
| Hou, Y | 1 |
| Shan, J | 2 |
| Li, M | 1 |
| Chen, C | 1 |
| Zhou, Y | 2 |
| Shan, E | 2 |
| Wang, J | 1 |
| Sun, H | 1 |
| Ma, R | 1 |
| Zhang, J | 2 |
| Chen, Y | 1 |
| Li, X | 1 |
| Çelebi, A | 1 |
| Dörtbudak, MB | 1 |
| Keskinrüzgar, A | 1 |
| Yüksel, H | 1 |
| Aksoy, N | 1 |
| Sen, E | 1 |
| Sukmasari, S | 1 |
| Özakpınar, ÖB | 1 |
| Arıcıoğlu, F | 1 |
| Yücel, YY | 1 |
| Dumlu, MR | 1 |
| Doolaanea, AA | 1 |
| AbdulRahman, MN | 1 |
| Olgac, V | 1 |
| Bozkan, P | 1 |
| Ozen, B | 1 |
| Li, L | 1 |
| Xuan, Y | 1 |
| Zhu, B | 1 |
| Wang, X | 1 |
| Tian, X | 1 |
| Zhao, L | 1 |
| Jiang, X | 2 |
| Wen, N | 1 |
| Tian, MM | 1 |
| Wang, YS | 1 |
| Xiao, HB | 1 |
| Ogihara, T | 1 |
| Kagawa, M | 1 |
| Yamanaka, R | 1 |
| Imai, S | 1 |
| Itohara, K | 1 |
| Hira, D | 2 |
| Nakagawa, S | 1 |
| Yonezawa, A | 1 |
| Ito, M | 2 |
| Nakagawa, T | 1 |
| Terada, T | 2 |
| Matsubara, K | 1 |
| Zhao, Y | 1 |
| Mao, R | 1 |
| Yan, H | 1 |
| Zhang, Y | 1 |
| Ma, H | 1 |
| Tang, Y | 1 |
| Walladbegi, J | 4 |
| Dankis, M | 3 |
| Aydogdu, Ö | 3 |
| Jontell, M | 4 |
| Winder, M | 3 |
| Huang, J | 2 |
| Hwang, AYM | 2 |
| Jia, Y | 2 |
| Kim, B | 2 |
| Iskandar, M | 2 |
| Mohammed, AI | 3 |
| Cirillo, N | 3 |
| Vaezi, H | 2 |
| Rabbani, S | 2 |
| Mortazavi, SA | 2 |
| Kamalinejad, M | 2 |
| Haeri, A | 2 |
| Gomes, JT | 2 |
| Wanzeler, AMV | 2 |
| Júnior, SMA | 2 |
| Soares, RHFC | 1 |
| Oliveira, CP | 1 |
| Rodrigues, EM | 1 |
| Soares, BM | 2 |
| Alcantara, DDFA | 1 |
| Burbano, RMR | 1 |
| Tuji, FM | 2 |
| Celentano, A | 1 |
| Paolini, R | 1 |
| Low, JT | 1 |
| McCullough, MJ | 1 |
| O' Reilly, LA | 1 |
| Yamanobe, H | 1 |
| Yamamoto, K | 1 |
| Kishimoto, S | 1 |
| Nakai, K | 1 |
| Oseko, F | 1 |
| Yamamoto, T | 1 |
| Mazda, O | 1 |
| Kanamura, N | 1 |
| Hamidi, SP | 1 |
| Koohi-Hosseinabadi, O | 6 |
| Khaksar, S | 1 |
| Ghanbariasad, A | 1 |
| Dehghanian, AR | 1 |
| Dehghan, A | 1 |
| Haddadi, Z | 1 |
| Gorgin, R | 1 |
| Farjam, M | 1 |
| Alipanah, H | 1 |
| Hu, Q | 1 |
| Xu, J | 1 |
| Ke, J | 1 |
| Zhang, Z | 1 |
| Chu, T | 1 |
| Dilber, M | 1 |
| Suleyman, B | 1 |
| Mammadov, R | 1 |
| Suleyman, Z | 1 |
| Yavuzer, B | 1 |
| Gulaboglu, M | 1 |
| Erhan, E | 1 |
| Salcan, I | 1 |
| Suleyman, H | 1 |
| Choi, S | 1 |
| Shin, SH | 1 |
| Lee, HR | 1 |
| Sohn, KY | 1 |
| Yoon, SY | 1 |
| Kim, JW | 2 |
| Damrongrungruang, T | 1 |
| Panpitakkul, P | 1 |
| Somudorn, J | 1 |
| Sangchart, P | 1 |
| Mahakunakorn, P | 2 |
| Uthaiwat, P | 2 |
| Daduang, J | 2 |
| Panyatip, P | 1 |
| Puthongking, P | 1 |
| Priprem, A | 2 |
| Jung, H | 1 |
| Kim, HS | 1 |
| Lee, JH | 1 |
| Lee, JJ | 1 |
| Park, HS | 1 |
| Kawamata, R | 1 |
| Cuba, LF | 1 |
| Salum, FG | 1 |
| Guimarães, FS | 1 |
| Cherubini, K | 1 |
| Borghetti, RL | 1 |
| de Figueiredo, MAZ | 1 |
| Settasatian, C | 1 |
| Chio-Srichan, S | 1 |
| Lee, YC | 1 |
| Boonsiri, P | 1 |
| Ramos, MV | 2 |
| Freitas, APF | 1 |
| Leitão, RFC | 3 |
| Costa, DVS | 1 |
| Cerqueira, GS | 1 |
| Martins, DS | 1 |
| Martins, CS | 1 |
| Alencar, NMN | 2 |
| Freitas, LBN | 1 |
| Brito, GAC | 5 |
| Yan, P | 1 |
| Yin, H | 1 |
| Guo, W | 1 |
| Sun, X | 2 |
| Li, F | 1 |
| Huang, S | 1 |
| Bian, X | 1 |
| Wang, F | 1 |
| Zhang, F | 1 |
| Wang, B | 1 |
| Zhou, H | 1 |
| Zhou, C | 1 |
| Yin, L | 1 |
| Jiang, N | 1 |
| Wu, J | 2 |
| Liu, J | 1 |
| Song, D | 1 |
| He, X | 1 |
| Tanideh, N | 7 |
| Badie, A | 1 |
| Habibagahi, R | 1 |
| Haghnegahdar, S | 2 |
| Andisheh-Tadbir, A | 2 |
| Wagner, AD | 1 |
| Grothey, A | 2 |
| Andre, T | 1 |
| Dixon, JG | 1 |
| Wolmark, N | 1 |
| Haller, DG | 1 |
| Allegra, CJ | 1 |
| de Gramont, A | 2 |
| VanCutsem, E | 1 |
| Alberts, SR | 1 |
| George, TJ | 1 |
| O'Connell, MJ | 3 |
| Twelves, C | 1 |
| Taieb, J | 1 |
| Saltz, LB | 3 |
| Blanke, CD | 2 |
| Francini, E | 1 |
| Kerr, R | 1 |
| Yothers, G | 1 |
| Seitz, JF | 2 |
| Marsoni, S | 1 |
| Goldberg, RM | 4 |
| Shi, Q | 1 |
| Gupta, N | 1 |
| Ferreira, J | 1 |
| Hong, CHL | 1 |
| Tan, KS | 1 |
| Huang, YF | 2 |
| Liu, SP | 1 |
| Muo, CH | 1 |
| Chen, HJ | 1 |
| Liao, YF | 1 |
| Chiu, KM | 1 |
| Chen, CC | 1 |
| Tsai, CH | 1 |
| Hong, HH | 2 |
| Chang, CT | 2 |
| Rodrigues, AB | 1 |
| Aguiar, MIF | 1 |
| Oliveira, PP | 1 |
| Alves, NP | 1 |
| Silva, RA | 1 |
| Vitorino, WO | 1 |
| Lopes, TSS | 1 |
| de Morais, EF | 1 |
| Batista Severo, ML | 1 |
| Dantas Martins, HD | 1 |
| Trevizani Martins, MA | 1 |
| de Almeida Freitas, R | 1 |
| Al-Taie, A | 1 |
| Koseoglu, A | 1 |
| Kim, DR | 1 |
| Kim, J | 2 |
| Oh, JY | 1 |
| Kim, HY | 2 |
| Kim, YJ | 1 |
| Chang, MS | 2 |
| Xing, X | 1 |
| Meng, F | 1 |
| Zhong, D | 1 |
| Falvella, FS | 1 |
| Luoni, M | 1 |
| Cheli, S | 1 |
| Fava, S | 1 |
| Cergnul, M | 1 |
| Harada, K | 1 |
| Ferdous, T | 1 |
| Kobayashi, H | 1 |
| Ueyama, Y | 1 |
| Ranjbar, Z | 2 |
| Sepehrimanesh, M | 2 |
| AndisheTadbir, A | 1 |
| Poorbaghi, SL | 1 |
| Bahranifard, H | 1 |
| Koohi-Hosseinabadi, M | 1 |
| Iraji, A | 2 |
| Dos Santos Filho, EX | 1 |
| da Silva, ACG | 1 |
| de Ávila, RI | 1 |
| Batista, AC | 2 |
| Marreto, RN | 2 |
| Lima, EM | 1 |
| de Oliveira, CMA | 1 |
| Mendonça, EF | 1 |
| Valadares, MC | 2 |
| Silva, VCD | 1 |
| Martins, CDS | 1 |
| Freire, GE | 1 |
| Aragão, KS | 1 |
| Wanderley, CWS | 1 |
| Freitas, MR | 1 |
| Ribeiro, SB | 1 |
| Araújo Júnior, RF | 2 |
| Leitão, RC | 1 |
| Barbosa, MM | 1 |
| Garcia, VB | 2 |
| Medeiros, AC | 1 |
| Medeiros, CACX | 2 |
| Sottili, M | 1 |
| Mangoni, M | 1 |
| Gerini, C | 1 |
| Salvatore, G | 1 |
| Castiglione, F | 1 |
| Desideri, I | 1 |
| Bonomo, P | 1 |
| Meattini, I | 1 |
| Greto, D | 1 |
| Loi, M | 1 |
| Francolini, G | 1 |
| Perna, M | 1 |
| Grassi, R | 1 |
| Biti, G | 1 |
| Livi, L | 1 |
| Gouveia, EHH | 1 |
| Henriques, HYB | 1 |
| Chaves, RH | 1 |
| Salgado, HLC | 1 |
| Santos, AS | 1 |
| Shimamura, Y | 2 |
| Terada, H | 2 |
| Sobue, T | 2 |
| Bertolini, M | 1 |
| Thompson, A | 2 |
| Peterson, DE | 3 |
| Diaz, PI | 2 |
| Dongari-Bagtzoglou, A | 2 |
| Smith, SA | 1 |
| Grayson, AK | 1 |
| Murdoch, C | 1 |
| Colley, HE | 1 |
| Pastorino, A | 1 |
| Di Bartolomeo, M | 1 |
| Maiello, E | 1 |
| Iaffaioli, V | 1 |
| Ciuffreda, L | 1 |
| Fasola, G | 1 |
| Di Costanzo, F | 1 |
| Frassineti, GL | 2 |
| Marchetti, P | 1 |
| Antoniotti, C | 1 |
| Leone, F | 1 |
| Zaniboni, A | 1 |
| Aprile, G | 1 |
| Zilocchi, C | 1 |
| Sobrero, A | 3 |
| Bordonaro, R | 1 |
| Kamiki, Y | 1 |
| Araújo, AA | 1 |
| Araújo, LS | 1 |
| Costa, DVDS | 1 |
| Guerra, GCB | 1 |
| Lima, MLS | 1 |
| Idayu Mat Nawi, R | 1 |
| Lei Chui, P | 1 |
| Wan Ishak, WZ | 1 |
| Hsien Chan, CM | 1 |
| Dote, S | 1 |
| Itakura, S | 1 |
| Kamei, K | 1 |
| Noda, S | 1 |
| Kobayashi, Y | 1 |
| Park, JW | 1 |
| Oh, J | 1 |
| Ko, SJ | 1 |
| Okamoto, K | 1 |
| Ninomiya, I | 1 |
| Yamaguchi, T | 5 |
| Terai, S | 1 |
| Nakanuma, S | 1 |
| Kinoshita, J | 1 |
| Makino, I | 1 |
| Nakamura, K | 2 |
| Miyashita, T | 1 |
| Tajima, H | 1 |
| Takamura, H | 1 |
| Fushida, S | 1 |
| Ohta, T | 1 |
| Schmidt, TR | 1 |
| Curra, M | 3 |
| Wagner, VP | 1 |
| de Oliveira, AC | 1 |
| Barbosa, SCM | 1 |
| Pereira, VBM | 1 |
| Wong, DVT | 1 |
| Santana, APM | 1 |
| Lucetti, LT | 1 |
| Carvalho, LL | 1 |
| Barbosa, CRN | 1 |
| Callado, RB | 1 |
| Silva, CAA | 1 |
| Lopes, CDH | 1 |
| Lima-Júnior, RCP | 1 |
| Alinca, SB | 1 |
| Saglam, E | 1 |
| Kandas, NO | 1 |
| Okcu, O | 1 |
| Yilmaz, N | 1 |
| Goncu, B | 1 |
| Dogan, MA | 1 |
| Hong, BY | 1 |
| Choquette, L | 1 |
| Dupuy, AK | 1 |
| Burleson, JA | 1 |
| Salner, AL | 1 |
| Schauer, PK | 1 |
| Joshi, P | 1 |
| Fox, E | 1 |
| Shin, DG | 1 |
| Weinstock, GM | 1 |
| Strausbaugh, LD | 1 |
| Burns, KE | 1 |
| Allright, D | 1 |
| Porter, D | 1 |
| Findlay, MP | 1 |
| Helsby, NA | 1 |
| Schwartzberg, LS | 1 |
| Tauer, KW | 1 |
| Hermann, RC | 1 |
| Makari-Judson, G | 1 |
| Isaacs, C | 1 |
| Beck, JT | 1 |
| Kaklamani, V | 1 |
| Stepanski, EJ | 1 |
| Rugo, HS | 1 |
| Wang, W | 1 |
| Bell-McGuinn, K | 1 |
| Kirshner, JJ | 1 |
| Eisenberg, P | 1 |
| Emanuelson, R | 1 |
| Keaton, M | 1 |
| Levine, E | 1 |
| Medgyesy, DC | 1 |
| Qamar, R | 1 |
| Starr, A | 1 |
| Ro, SK | 1 |
| Lokker, NA | 1 |
| Hudis, CA | 1 |
| Won, JH | 1 |
| Ji, JE | 1 |
| Ahn, KH | 1 |
| Kim, SK | 1 |
| Choi, JM | 1 |
| Ha, HC | 1 |
| Kim, HM | 1 |
| Yun, CK | 1 |
| Han, K | 1 |
| Kim, DK | 1 |
| Mazzeo, MA | 1 |
| Linares, JA | 1 |
| López, MM | 1 |
| Bachmeier, E | 1 |
| Wietz, FM | 1 |
| Galván, V | 1 |
| Valentinuzzi, MC | 1 |
| Riveros, JA | 1 |
| Finkelberg, A | 1 |
| Lin, HX | 2 |
| Hua, YJ | 1 |
| Chen, QY | 1 |
| Luo, DH | 2 |
| Sun, R | 1 |
| Qiu, F | 2 |
| Mo, HY | 1 |
| Mai, HQ | 1 |
| Guo, X | 2 |
| Xian, LJ | 1 |
| Hong, MH | 2 |
| Guo, L | 2 |
| Kochi, M | 1 |
| Akiyama, Y | 1 |
| Aoki, T | 1 |
| Hagiwara, K | 1 |
| Takahashi, T | 1 |
| Hironaka, K | 1 |
| Teranishi, F | 1 |
| Osuka, F | 1 |
| Takeuchi, M | 1 |
| Fujii, M | 2 |
| Nakajima, T | 1 |
| Davarmanesh, M | 2 |
| Miri, R | 1 |
| Tadbir, AA | 3 |
| Saghiri, MA | 2 |
| Garcia-Godoy, F | 2 |
| Asatourian, A | 1 |
| Scardina, GA | 1 |
| Cacioppo, A | 1 |
| Messina, P | 1 |
| Likhacheva, A | 1 |
| Jhingran, A | 1 |
| Bodurka, DC | 1 |
| Sun, C | 1 |
| Sam, M | 1 |
| Eifel, PJ | 1 |
| Hamaker, ME | 1 |
| Seynaeve, C | 1 |
| Wymenga, AN | 2 |
| van Tinteren, H | 1 |
| Nortier, JW | 1 |
| Maartense, E | 1 |
| de Graaf, H | 1 |
| de Jongh, FE | 1 |
| Braun, JJ | 1 |
| Los, M | 1 |
| Schrama, JG | 1 |
| van Leeuwen-Stok, AE | 1 |
| de Groot, SM | 1 |
| Smorenburg, CH | 1 |
| Yoshino, F | 1 |
| Yoshida, A | 1 |
| Nakajima, A | 1 |
| Wada-Takahashi, S | 1 |
| Takahashi, SS | 1 |
| Lee, MC | 1 |
| Saif, MW | 1 |
| Lee, AM | 1 |
| Offer, SM | 1 |
| McConnell, K | 1 |
| Relias, V | 1 |
| Diasio, RB | 1 |
| Liu, Y | 1 |
| Wu, W | 1 |
| Hong, W | 1 |
| Huang, Q | 1 |
| Horii, K | 1 |
| Kanayama, T | 1 |
| Miyamoto, H | 3 |
| Kohgo, T | 1 |
| Tsuchimochi, T | 1 |
| Shigetomi, T | 1 |
| Yokoi, M | 1 |
| Karaca, H | 1 |
| Bozkurt, O | 1 |
| Ozaslan, E | 1 |
| Baldane, S | 1 |
| Berk, V | 1 |
| Inanc, M | 1 |
| Duran, AO | 1 |
| Dikilitas, M | 2 |
| Er, O | 1 |
| Ozkan, M | 1 |
| Namazi, F | 1 |
| Andisheh Tadbir, A | 1 |
| Ebrahimi, H | 1 |
| Yoshida, K | 1 |
| Yoshioka, M | 1 |
| Okamura, H | 1 |
| Moriyama, S | 1 |
| Kawazoe, K | 1 |
| Grenier, D | 1 |
| Hinode, D | 1 |
| Enami, A | 1 |
| Masuda, N | 1 |
| Yamamura, J | 1 |
| Mizutani, M | 1 |
| Yasojima, H | 1 |
| Shikata, A | 1 |
| Masaoka, M | 1 |
| Takada, S | 1 |
| Bamba, N | 1 |
| Yamamoto, M | 1 |
| Abe, M | 1 |
| Makihara, K | 1 |
| Skeff, MA | 1 |
| Brito, GA | 6 |
| de Oliveira, MG | 1 |
| Braga, CM | 1 |
| Cavalcante, MM | 1 |
| Baldim, V | 1 |
| Holanda-Afonso, RC | 1 |
| Silva-Boghossian, CM | 1 |
| Colombo, AP | 1 |
| Ribeiro, RA | 6 |
| Moura-Neto, V | 1 |
| Leitão, RF | 4 |
| Cruz, Éde P | 1 |
| Campos, L | 2 |
| Pereira, Fda S | 1 |
| Magliano, GC | 1 |
| Benites, BM | 1 |
| Ballester, RY | 1 |
| Takano, H | 1 |
| Momota, Y | 1 |
| Kani, K | 1 |
| Aota, K | 1 |
| Yamamura, Y | 1 |
| Yamanoi, T | 1 |
| Azuma, M | 1 |
| Lima, Gde M | 1 |
| Severo, MC | 1 |
| Santana-Melo, Gde F | 1 |
| Carvalho, MA | 1 |
| Vilela-Goulart, Md | 2 |
| Salgado, MA | 1 |
| Gomes, MF | 2 |
| Matsuda, C | 1 |
| Munemoto, Y | 1 |
| Mishima, H | 1 |
| Nagata, N | 1 |
| Oshiro, M | 1 |
| Kataoka, M | 1 |
| Sakamoto, J | 1 |
| Aoyama, T | 1 |
| Morita, S | 1 |
| Kono, T | 1 |
| Ohnuma, H | 1 |
| Sato, Y | 1 |
| Hirakawa, M | 1 |
| Okagawa, Y | 1 |
| Osuga, T | 1 |
| Hayashi, T | 1 |
| Sato, T | 1 |
| Miyanishi, K | 1 |
| Kobune, M | 1 |
| Takimoto, R | 1 |
| Sagawa, T | 1 |
| Hori, M | 1 |
| Someya, M | 1 |
| Nakata, K | 1 |
| Sakata, K | 1 |
| Takayama, T | 1 |
| Kato, J | 1 |
| Hsiang, CY | 1 |
| Ho, TY | 1 |
| Wu, CZ | 1 |
| Mardani, M | 1 |
| Afra, SM | 1 |
| Modarresi, F | 1 |
| Abdel-Rahman, O | 1 |
| ElHalawani, H | 1 |
| Essam-Eldin, S | 1 |
| Riley, P | 1 |
| Glenny, AM | 1 |
| Worthington, HV | 1 |
| Littlewood, A | 1 |
| Clarkson, JE | 1 |
| McCabe, MG | 1 |
| Pellicioli, AC | 2 |
| Filho, NA | 1 |
| Ochs, G | 1 |
| Matte, Ú | 1 |
| Filho, MS | 1 |
| Martins, MA | 3 |
| Yamaguchi, K | 1 |
| Ono, K | 1 |
| Hitomi, S | 1 |
| Nodai, T | 1 |
| Goto, T | 1 |
| Harano, N | 1 |
| Watanabe, S | 4 |
| Inoue, H | 1 |
| Miyano, K | 1 |
| Uezono, Y | 1 |
| Matoba, M | 1 |
| Inenaga, K | 1 |
| Ala, S | 2 |
| Saeedi, M | 2 |
| Janbabai, G | 1 |
| Ganji, R | 1 |
| Azhdari, E | 1 |
| Shiva, A | 1 |
| Molina Prats, P | 1 |
| Gómez Garcia, F | 1 |
| Martinez Diaz, F | 1 |
| Amaral Mendes, R | 1 |
| Lopez-Jornet, P | 1 |
| Nakata, Y | 1 |
| Ijichi, K | 1 |
| Hanai, N | 1 |
| Nishikawa, D | 1 |
| Suzuki, H | 1 |
| Hirakawa, H | 1 |
| Kodaira, T | 1 |
| Fujimoto, Y | 1 |
| Fujii, T | 1 |
| Miyazaki, T | 1 |
| Shimizu, T | 1 |
| Hasegawa, Y | 1 |
| Turkeli, M | 1 |
| Aldemir, MN | 1 |
| Bingol, F | 1 |
| Dogan, C | 1 |
| Kara, A | 1 |
| Bossi, P | 1 |
| Bergamini, C | 1 |
| Miceli, R | 1 |
| Cova, A | 1 |
| Orlandi, E | 1 |
| Resteghini, C | 1 |
| Locati, L | 1 |
| Alfieri, S | 1 |
| Imbimbo, M | 1 |
| Granata, R | 1 |
| Mariani, L | 1 |
| Iacovelli, NA | 1 |
| Huber, V | 1 |
| Cavallo, A | 1 |
| Licitra, L | 1 |
| Rivoltini, L | 1 |
| Spivakovsky, S | 1 |
| Gümüş, S | 1 |
| Yarıktaş, M | 1 |
| Nazıroğlu, M | 1 |
| Uğuz, AC | 1 |
| Aynali, G | 1 |
| Başpınar, Ş | 1 |
| Mehriar, P | 1 |
| Okada, T | 1 |
| Nakajima, Y | 1 |
| Nishikage, T | 1 |
| Ryotokuji, T | 1 |
| Miyawaki, Y | 1 |
| Hoshino, A | 1 |
| Tokairin, Y | 1 |
| Kawada, K | 1 |
| Nagai, K | 1 |
| Kawano, T | 1 |
| Nesadal de Souza, D | 1 |
| Suemaru, K | 4 |
| Cui, R | 2 |
| Li, B | 2 |
| Okihara, K | 1 |
| Hashimoto, K | 1 |
| Yamada, H | 1 |
| Araki, H | 4 |
| Teixeira, RT | 1 |
| Rangel, DC | 1 |
| Niccoli-Filho, W | 1 |
| Topuz, E | 1 |
| Derin, D | 1 |
| Can, G | 1 |
| Kürklü, E | 1 |
| Cinar, S | 1 |
| Aykan, F | 1 |
| Cevikbaş, A | 1 |
| Dişçi, R | 1 |
| Durna, Z | 1 |
| Sakar, B | 1 |
| Saglam, S | 1 |
| Tanyeri, H | 1 |
| Deniz, G | 1 |
| Gürer, U | 1 |
| Taş, F | 1 |
| Guney, N | 1 |
| Aydiner, A | 1 |
| Sacono, NT | 1 |
| Costa, CA | 1 |
| Bagnato, VS | 1 |
| Abreu-e-Lima, FC | 1 |
| Lopes, NN | 2 |
| Plapler, H | 2 |
| Chavantes, MC | 2 |
| Lalla, RV | 2 |
| Yoshimura, EM | 2 |
| Alves, MT | 2 |
| Lee, YJ | 1 |
| Lee, HJ | 1 |
| Jeong, KC | 1 |
| Kang, JG | 1 |
| Lee, SH | 1 |
| Kim, YT | 1 |
| Maiguma, T | 1 |
| Kaji, H | 2 |
| Teshima, D | 1 |
| Kovács, AF | 1 |
| Eberlein, K | 1 |
| Hülsmann, T | 1 |
| Mignogna, MD | 1 |
| Fortuna, G | 1 |
| Falleti, J | 1 |
| Leuci, S | 1 |
| Hidaka, N | 1 |
| Sakanaka, M | 1 |
| Barker, NP | 1 |
| Akhmadullina, LI | 1 |
| Rodionova, I | 1 |
| Sherman, NZ | 1 |
| Davidenko, IS | 1 |
| Rakovskaya, GN | 1 |
| Gotovkin, EA | 1 |
| Shinkarev, SA | 1 |
| Kopp, MV | 1 |
| Kulikov, EP | 1 |
| Moiseyenko, VM | 1 |
| Gertner, JM | 1 |
| Firsov, I | 1 |
| Tuleneva, T | 1 |
| Yarosh, A | 1 |
| Woon, CW | 1 |
| Panahi, Y | 1 |
| Okhovatian, A | 1 |
| Bazzaz, N | 1 |
| Naghizadeh, MM | 1 |
| Buiret, G | 1 |
| Combe, C | 1 |
| Favrel, V | 1 |
| Pommier, P | 1 |
| Martin, L | 1 |
| Ecochard, R | 1 |
| Fayette, J | 1 |
| Tartas, S | 1 |
| Ramade, A | 1 |
| Céruse, P | 1 |
| Shueng, PW | 1 |
| Wu, LJ | 1 |
| Chen, SY | 3 |
| Hsiao, CH | 1 |
| Tien, HJ | 1 |
| Cheng, PW | 1 |
| Kuo, YS | 1 |
| Chen, YJ | 1 |
| Chen, CA | 1 |
| Hsieh, PY | 1 |
| Hsieh, CH | 1 |
| Baena-Cañada, JM | 1 |
| Martínez, MJ | 1 |
| García-Olmedo, O | 1 |
| Jiménez-Bárcenas, R | 1 |
| Muriel-Cueto, P | 1 |
| Bin, Q | 1 |
| Li, J | 1 |
| Liao, C | 1 |
| Cao, Y | 1 |
| Gao, F | 1 |
| Pavesi, VC | 2 |
| Lopez, TC | 1 |
| Sant'Ana Filho, M | 2 |
| Bussadori, SK | 1 |
| Fernandes, KP | 1 |
| Mesquita-Ferrari, RA | 1 |
| Clavel, S | 1 |
| Fortin, B | 1 |
| Després, P | 1 |
| Donath, D | 1 |
| Soulières, D | 1 |
| Khaouam, N | 1 |
| Charpentier, D | 1 |
| Bélair, M | 1 |
| Guertin, L | 1 |
| Nguyen-Tan, PF | 1 |
| Rades, D | 1 |
| Kronemann, S | 1 |
| Meyners, T | 1 |
| Bohlen, G | 1 |
| Tribius, S | 1 |
| Kazic, N | 1 |
| Schroeder, U | 1 |
| Hakim, SG | 1 |
| Schild, SE | 1 |
| Dunst, J | 1 |
| Medeiros, CA | 1 |
| Macedo, RN | 1 |
| Barboza, DR | 1 |
| Gomes, AS | 1 |
| Nogueira, NA | 1 |
| Alencar, NM | 1 |
| da Silva, MA | 1 |
| Wu, SX | 1 |
| Cui, TT | 1 |
| Zhao, C | 1 |
| Pan, JJ | 1 |
| Xu, BY | 1 |
| Tian, Y | 1 |
| Cui, NJ | 1 |
| Bhide, SA | 2 |
| Gulliford, S | 1 |
| Fowler, J | 1 |
| Rosenfelder, N | 1 |
| Newbold, K | 1 |
| Harrington, KJ | 2 |
| Nutting, CM | 2 |
| Fleckenstein, J | 1 |
| Kühne, M | 1 |
| Seegmüller, K | 1 |
| Derschang, S | 1 |
| Melchior, P | 1 |
| Gräber, S | 1 |
| Fricke, A | 1 |
| Rübe, CE | 1 |
| Rübe, C | 1 |
| Isaev, PA | 1 |
| Medvedev, VS | 1 |
| Pasov, VV | 1 |
| Semin, DIu | 1 |
| Derbugov, DN | 1 |
| Pol'kin, VV | 1 |
| Terekhov, OV | 1 |
| Thukral, A | 1 |
| Metz, J | 1 |
| Hwang, WT | 1 |
| O'Dwyer, P | 1 |
| Plastaras, J | 1 |
| Both, S | 1 |
| Bar-Ad, V | 1 |
| Ad, VB | 1 |
| Miah, AB | 1 |
| Guerrero-Urbano, MT | 1 |
| Clark, C | 1 |
| Bidmead, AM | 1 |
| St Rose, S | 1 |
| Barbachano, Y | 1 |
| A'hern, R | 1 |
| Tanay, M | 1 |
| Hickey, J | 1 |
| Nicol, R | 1 |
| Newbold, KL | 1 |
| Best, SR | 1 |
| Ha, PK | 1 |
| Blanco, RG | 1 |
| Saunders, JR | 1 |
| Zinreich, ES | 1 |
| Levine, MA | 1 |
| Pai, SI | 1 |
| Walker, M | 1 |
| Trachta, J | 1 |
| Ulmer, K | 1 |
| Murakami, P | 1 |
| Thompson, R | 1 |
| Califano, JA | 1 |
| Messing, BP | 1 |
| Sugisaki, T | 1 |
| Kawakami, K | 1 |
| Nemoto, M | 1 |
| Kawata, K | 1 |
| Ishibashi, M | 2 |
| Fujiki, Y | 1 |
| Mishima, Y | 1 |
| Yokoyama, M | 1 |
| Takahashi, S | 2 |
| Hatake, K | 1 |
| Hama, T | 1 |
| Winterhalder, R | 1 |
| Hoesli, P | 1 |
| Delmore, G | 1 |
| Pederiva, S | 1 |
| Bressoud, A | 1 |
| Hermann, F | 1 |
| von Moos, R | 1 |
| Bot, BM | 1 |
| Thomas, DM | 1 |
| Bleyer, A | 1 |
| Kohne, CH | 1 |
| Seymour, MT | 2 |
| Sargent, DJ | 2 |
| Kabeya, M | 1 |
| Ina, K | 1 |
| Yuasa, S | 1 |
| Kikuchi, F | 1 |
| Tajiri, C | 1 |
| Kato, T | 1 |
| Hibi, S | 1 |
| Minagawa, Y | 1 |
| Furuta, R | 1 |
| Kayukawa, S | 1 |
| Kataoka, T | 1 |
| Kawai, M | 1 |
| Yen, SH | 3 |
| Wang, LW | 1 |
| Lin, YH | 1 |
| Jen, YM | 1 |
| Chung, YL | 1 |
| Katrancı, N | 1 |
| Ovayolu, N | 1 |
| Ovayolu, O | 1 |
| Sevinc, A | 2 |
| Cen, P | 1 |
| Liu, C | 1 |
| Du, XL | 1 |
| Sanguineti, G | 1 |
| Sormani, MP | 1 |
| Marur, S | 1 |
| Gunn, GB | 1 |
| Rao, N | 1 |
| Cianchetti, M | 1 |
| Ricchetti, F | 1 |
| McNutt, T | 1 |
| Wu, B | 1 |
| Forastiere, A | 1 |
| Fukui, T | 1 |
| Itoh, Y | 1 |
| Orihara, M | 1 |
| Yoshizawa, K | 1 |
| Takeda, H | 1 |
| Kawada, S | 1 |
| Yoshioka, T | 1 |
| Fukazawa, M | 1 |
| Kawaguchi, H | 1 |
| Shigematsu, H | 1 |
| Koga, C | 1 |
| Mori, E | 1 |
| Nishimura, S | 1 |
| Nakamura, Y | 1 |
| Satou, S | 1 |
| Sawamura, K | 1 |
| Kashiwaba, K | 1 |
| Ohno, S | 1 |
| Cunha, CB | 1 |
| Eduardo, FP | 1 |
| Zezell, DM | 1 |
| Bezinelli, LM | 1 |
| Shitara, PP | 1 |
| Correa, L | 1 |
| Tomita, M | 1 |
| Matsuyama, H | 1 |
| Yamazaki, K | 1 |
| Sato, K | 1 |
| Freitas, AP | 1 |
| Bitencourt, FS | 1 |
| de Alencar, NM | 1 |
| Lima-Júnior, RC | 1 |
| Vale, ML | 2 |
| Qi, WX | 1 |
| Tang, LN | 1 |
| He, AN | 1 |
| Shen, Z | 1 |
| Yao, Y | 1 |
| Aguilar-Ponce, JL | 1 |
| Granados-García, M | 1 |
| Cruz López, JC | 1 |
| Maldonado-Magos, F | 1 |
| Alvarez-Avitia, MA | 1 |
| Arrieta, O | 1 |
| González-Ramírez, I | 1 |
| Lara-Cruz, G | 1 |
| Martinez-Juárez, I | 1 |
| Medina-Santillan, R | 1 |
| Castillo-Hernández, C | 1 |
| De la Garza-Salazar, J | 1 |
| Lauxen, IS | 1 |
| Carrard, VC | 1 |
| Miki, I | 1 |
| Nakamura, T | 1 |
| Kuwahara, A | 1 |
| Yamamori, M | 1 |
| Nishiguchi, K | 1 |
| Tamura, T | 1 |
| Okuno, T | 1 |
| Omatsu, H | 1 |
| Mizuno, S | 1 |
| Hirai, M | 1 |
| Azuma, T | 1 |
| Sakaeda, T | 1 |
| Nomura, M | 1 |
| Kamata, M | 1 |
| Kojima, H | 1 |
| Hayashi, K | 1 |
| Sawada, S | 1 |
| Tavakoli, P | 1 |
| Amanat, D | 1 |
| Samani, SM | 1 |
| Tamadon, A | 1 |
| Francois, E | 1 |
| Bennouna, J | 1 |
| Chamorey, E | 1 |
| Etienne-Grimaldi, MC | 1 |
| Renée, N | 1 |
| Senellart, H | 1 |
| Michel, C | 1 |
| Follana, P | 1 |
| Mari, V | 1 |
| Douillard, JY | 1 |
| Milano, G | 3 |
| Takechi, K | 1 |
| Imai, K | 1 |
| Russo, F | 1 |
| Linsalata, M | 1 |
| Clemente, C | 1 |
| D'Attoma, B | 1 |
| Orlando, A | 1 |
| Campanella, G | 1 |
| Giotta, F | 1 |
| Riezzo, G | 1 |
| Clarke, J | 2 |
| Butler, R | 1 |
| Howarth, G | 1 |
| Read, L | 1 |
| Regester, G | 2 |
| Takahashi, K | 3 |
| Mori, T | 3 |
| Ohue, M | 1 |
| Mohiuddin, M | 1 |
| Marks, G | 1 |
| Marks, J | 1 |
| Francini, G | 2 |
| Petrioli, R | 2 |
| Messinese, S | 1 |
| Pozzessere, D | 1 |
| Marsili, S | 1 |
| Correale, P | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Leonard, P | 1 |
| James, R | 1 |
| Hochhauser, D | 1 |
| Ledermann, JA | 1 |
| Rothenberg, ML | 1 |
| Nottage, M | 1 |
| McLachlan, SA | 1 |
| Brittain, MA | 1 |
| Oza, A | 1 |
| Hedley, D | 1 |
| Feld, R | 2 |
| Siu, LL | 1 |
| Pond, G | 1 |
| Moore, MJ | 2 |
| van Kuilenburg, AB | 2 |
| Baars, JW | 1 |
| Meinsma, R | 1 |
| van Gennip, AH | 2 |
| Bocci, G | 1 |
| Danesi, R | 1 |
| Allegrini, G | 1 |
| Innocenti, F | 2 |
| Di Paolo, A | 1 |
| Falcone, A | 2 |
| Conte, PF | 1 |
| Del Tacca, M | 1 |
| Okabe, S | 1 |
| Ishikawa, T | 1 |
| Tanami, H | 1 |
| Kuwabara, H | 1 |
| Fukahara, T | 1 |
| Udagawa, M | 1 |
| Ootsukasa, S | 1 |
| Arai, T | 1 |
| Maruyama, S | 1 |
| Murase, N | 1 |
| Yamashita, H | 1 |
| Iwai, T | 1 |
| Rossi, A | 1 |
| Rosati, G | 2 |
| Colarusso, D | 2 |
| Manzione, L | 2 |
| Tebbutt, NC | 1 |
| Norman, AR | 1 |
| Cunningham, D | 3 |
| Allen, M | 1 |
| Chau, I | 1 |
| Oates, J | 1 |
| Hill, M | 2 |
| Alvarez, E | 1 |
| Fey, EG | 1 |
| Valax, P | 1 |
| Yim, Z | 1 |
| Peterson, JD | 1 |
| Mesri, M | 1 |
| Jeffers, M | 1 |
| Dindinger, M | 1 |
| Twomlow, N | 1 |
| Ghatpande, A | 1 |
| LaRochelle, WJ | 1 |
| Sonis, ST | 9 |
| Lichenstein, HS | 1 |
| ANSFIELD, FJ | 4 |
| CURRERI, AR | 1 |
| MALKASIAN, GD | 1 |
| DECKER, DG | 1 |
| MUSSEY, E | 1 |
| JOHNSON, CE | 1 |
| CUDMORE, JT | 1 |
| GROESBECK, HP | 1 |
| MOERTEL, CG | 5 |
| REITEMEIER, RJ | 2 |
| HAHN, RG | 3 |
| HURLEY, JD | 1 |
| Schmidberger, H | 1 |
| Rave-Fränk, M | 1 |
| Kim, S | 1 |
| Hille, A | 1 |
| Pradier, O | 1 |
| Hess, CF | 1 |
| Ura, T | 1 |
| Shirao, K | 2 |
| Han, JY | 1 |
| Lee, DH | 1 |
| Hong, EK | 1 |
| Yoon, SM | 1 |
| Chun, JH | 1 |
| Lee, HG | 1 |
| Lee, SY | 1 |
| Shin, EH | 1 |
| Lee, JS | 1 |
| Matsumoto, H | 2 |
| Arai, K | 2 |
| Iwasaki, Y | 2 |
| Katayanagi, S | 2 |
| Morvan, FO | 1 |
| Baroukh, B | 1 |
| Ledoux, D | 1 |
| Caruelle, JP | 1 |
| Barritault, D | 1 |
| Godeau, G | 1 |
| Saffar, JL | 1 |
| Schrijvers, D | 1 |
| Van Herpen, C | 1 |
| Kerger, J | 1 |
| Joosens, E | 1 |
| Van Laer, C | 1 |
| Awada, A | 1 |
| Van den Weyngaert, D | 1 |
| Nguyen, H | 1 |
| Le Bouder, C | 1 |
| Castelijns, JA | 1 |
| Kaanders, J | 1 |
| De Mulder, P | 1 |
| Vermorken, JB | 1 |
| Parulekar, W | 1 |
| de Marsh, RW | 1 |
| Wong, R | 2 |
| Mendenhall, W | 1 |
| Davey, P | 1 |
| Zlotecki, R | 1 |
| Berry, S | 1 |
| Rout, WR | 1 |
| Bjarnason, GA | 1 |
| Sykes, AJ | 1 |
| Slevin, NJ | 1 |
| MacDougall, RH | 1 |
| Ironside, JA | 1 |
| Mais, KL | 1 |
| Cohen, SM | 1 |
| Neugut, AI | 1 |
| Ghi, MG | 1 |
| Paccagnella, A | 2 |
| D'Amanzo, P | 1 |
| Mione, CA | 1 |
| Fasan, S | 1 |
| Paro, S | 1 |
| Mastromauro, C | 1 |
| Carnuccio, R | 1 |
| Turcato, G | 1 |
| Gatti, C | 1 |
| Pallini, A | 1 |
| Nascimben, O | 1 |
| Biason, R | 1 |
| Oniga, F | 1 |
| Medici, M | 1 |
| Rossi, F | 1 |
| Fila, G | 1 |
| Kuehr, T | 1 |
| Ruff, P | 1 |
| Rapoport, BL | 1 |
| Falk, S | 1 |
| Daniel, F | 1 |
| Jacobs, C | 1 |
| Davidson, N | 1 |
| Thaler, J | 1 |
| Boussard, B | 1 |
| Carmichael, J | 1 |
| Aksungur, P | 1 |
| Sungur, A | 1 |
| Unal, S | 1 |
| Iskit, AB | 1 |
| Squier, CA | 1 |
| Senel, S | 1 |
| Li, FY | 1 |
| Li, Q | 1 |
| Tucci, A | 1 |
| Rinaldi, A | 1 |
| Pizza, C | 1 |
| Reggiardo, G | 1 |
| Marsé, H | 1 |
| Van Cutsem, E | 2 |
| Valverde, S | 1 |
| Sternberg, CN | 1 |
| Reichardt, P | 1 |
| Holland, M | 1 |
| Undevia, SD | 1 |
| Kindler, HL | 2 |
| Janisch, L | 1 |
| Olson, SC | 1 |
| Schilsky, RL | 4 |
| Vogelzang, NJ | 2 |
| Kimmel, KA | 1 |
| Macek, TA | 1 |
| Ratain, MJ | 3 |
| Feng, JF | 1 |
| Lu, JW | 1 |
| Sun, XF | 1 |
| Di Lorenzo, G | 1 |
| Autorino, R | 1 |
| Giordano, A | 1 |
| Giuliano, M | 1 |
| D'Armiento, M | 1 |
| Bianco, AR | 1 |
| De Placido, S | 1 |
| Franchin, G | 1 |
| Vaccher, E | 1 |
| Gobitti, C | 1 |
| Minatel, E | 1 |
| Politi, D | 1 |
| Talamini, R | 1 |
| Di Gennaro, G | 1 |
| Savignano, G | 1 |
| Trovò, MG | 1 |
| Tirelli, U | 1 |
| Barzan, L | 1 |
| Dörr, W | 1 |
| Bässler, S | 1 |
| Reichel, S | 1 |
| Spekl, K | 1 |
| Nikoletti, S | 1 |
| Hyde, S | 1 |
| Shaw, T | 1 |
| Myers, H | 1 |
| Kristjanson, LJ | 1 |
| Lima, V | 1 |
| Cunha, FQ | 2 |
| Rebouças, CG | 1 |
| Falcão, BA | 1 |
| Augusto, RF | 1 |
| Souza, ML | 1 |
| Leitão, BT | 1 |
| Lin, A | 1 |
| Jabbari, S | 1 |
| Worden, FP | 1 |
| Bradford, CR | 1 |
| Chepeha, DB | 1 |
| Teknos, TN | 1 |
| Liao, JJ | 1 |
| Nyquist, GG | 1 |
| Tsien, C | 1 |
| Schipper, MJ | 1 |
| Urba, S | 1 |
| Wolf, GT | 1 |
| Eisbruch, A | 1 |
| Baydar, M | 1 |
| Aydogdu, I | 1 |
| Yamshita, Y | 1 |
| Shikimori, M | 1 |
| Goto, M | 1 |
| Kwong, DL | 1 |
| Sham, JS | 1 |
| Leung, LH | 1 |
| Cheng, AC | 1 |
| Ng, WM | 1 |
| Kwong, PW | 1 |
| Lui, WM | 1 |
| Yau, CC | 1 |
| Wu, PM | 1 |
| Wei, W | 1 |
| Au, G | 1 |
| Cho, SA | 1 |
| Park, JH | 2 |
| Seok, SH | 1 |
| Juhn, JH | 1 |
| Kim, SJ | 1 |
| Ji, HJ | 1 |
| Choo, YS | 1 |
| Farker, K | 1 |
| Merkel, U | 1 |
| Wedding, U | 1 |
| Hippius, M | 1 |
| Höffken, K | 2 |
| Hoffmann, A | 1 |
| Jones, JA | 1 |
| Avritscher, EB | 1 |
| Cooksley, CD | 1 |
| Michelet, M | 1 |
| Bekele, BN | 1 |
| Elting, LS | 1 |
| Cerchietti, LC | 1 |
| Navigante, AH | 1 |
| Lutteral, MA | 1 |
| Castro, MA | 1 |
| Kirchuk, R | 1 |
| Bonomi, M | 1 |
| Cabalar, ME | 1 |
| Roth, B | 1 |
| Negretti, G | 1 |
| Sheinker, B | 1 |
| Uchima, P | 1 |
| Papadeas, E | 1 |
| Naxakis, S | 1 |
| Riga, M | 1 |
| Kalofonos, Ch | 1 |
| Berg, DT | 1 |
| Bellaguarda, EA | 2 |
| Macedo, FD | 2 |
| Silva, LR | 2 |
| Oriá, RB | 1 |
| Choi, K | 1 |
| Lee, SS | 1 |
| Oh, SJ | 1 |
| Lim, SY | 2 |
| Jeon, WK | 1 |
| Oh, TY | 1 |
| Mitsuhashi, H | 1 |
| Rosen, LS | 2 |
| Abdi, E | 1 |
| Davis, ID | 1 |
| Gutheil, J | 1 |
| Schnell, FM | 1 |
| Zalcberg, J | 1 |
| Cesano, A | 1 |
| Gayko, U | 1 |
| Chen, MG | 1 |
| Clarke, S | 1 |
| Mauger, CA | 1 |
| Butler, RN | 1 |
| Geier, MS | 1 |
| Tooley, KL | 1 |
| Howarth, GS | 1 |
| Lara, RN | 1 |
| da Guerra, EN | 1 |
| de Melo, NS | 1 |
| Lira, AM | 1 |
| Sousa, RB | 1 |
| Wilder-Smith, P | 1 |
| Hammer-Wilson, MJ | 1 |
| Wang, Q | 1 |
| Osann, K | 1 |
| Chen, Z | 1 |
| Wigdor, H | 1 |
| Schwartz, J | 1 |
| Epstein, J | 1 |
| Larsen, S | 1 |
| Serup-Hansen, E | 1 |
| Andersen, LJ | 1 |
| Lindeløv, B | 1 |
| McCulloch, T | 1 |
| Adimi, P | 1 |
| Bastholt, L | 1 |
| Haines, IE | 1 |
| Yamamitsu, S | 1 |
| Kimura, H | 1 |
| Yamada, Y | 1 |
| Inui, N | 1 |
| Hiyama, S | 1 |
| Hirata, K | 1 |
| Kimura, Y | 1 |
| Shirasaka, T | 1 |
| Xie, FY | 1 |
| Qi, SN | 1 |
| Hu, WH | 1 |
| Zou, GR | 1 |
| Peng, M | 1 |
| Li, JS | 1 |
| Kim, SG | 1 |
| Oh, SY | 1 |
| Kwon, HC | 1 |
| Lee, S | 1 |
| Kim, JH | 1 |
| Kim, SH | 1 |
| Kim, HJ | 1 |
| Gong, ZJ | 1 |
| Ren, JQ | 1 |
| Kong, G | 1 |
| Qing, DJ | 1 |
| Liu, H | 1 |
| Liang, YQ | 1 |
| Sorensen, JB | 1 |
| Skovsgaard, T | 1 |
| Bork, E | 1 |
| Damstrup, L | 1 |
| Ingeberg, S | 1 |
| Fox, RM | 2 |
| Woods, RL | 2 |
| Tattersall, MH | 1 |
| Piper, AA | 1 |
| Sampson, D | 1 |
| Kish, JA | 2 |
| Weaver, A | 2 |
| Jacobs, J | 2 |
| Cummings, G | 2 |
| Al-Sarraf, M | 2 |
| Bruckner, HW | 1 |
| Cohen, J | 1 |
| Aboud, A | 1 |
| Buzdar, AU | 2 |
| Yap, HY | 1 |
| Hortobagyi, GN | 2 |
| Blumenschein, GR | 1 |
| Windschitl, H | 1 |
| Scott, M | 1 |
| Schutt, A | 1 |
| McCormack, G | 1 |
| Everson, L | 1 |
| Cullinan, S | 1 |
| Gerstner, J | 1 |
| Krook, J | 1 |
| Laurie, J | 1 |
| Shreck, R | 1 |
| Lokich, J | 4 |
| Bothe, A | 1 |
| Fine, N | 1 |
| Perri, J | 1 |
| Sonis, S | 1 |
| Muska, A | 1 |
| O'Brien, J | 1 |
| Van Vugt, A | 2 |
| Langer-Safer, P | 1 |
| Keith, J | 2 |
| Verdi, CJ | 1 |
| Garewal, HS | 1 |
| Koenig, LM | 1 |
| Vaughn, B | 1 |
| Burkhead, T | 1 |
| Chan, AT | 1 |
| Teo, PM | 1 |
| Leung, TW | 1 |
| Leung, SF | 1 |
| Lee, WY | 1 |
| Yeo, W | 1 |
| Choi, PH | 1 |
| Johnson, PJ | 1 |
| Greenhouse, JB | 1 |
| Wasserman, L | 1 |
| Chi, KH | 2 |
| Chen, CH | 1 |
| Chan, WK | 2 |
| Chow, KC | 1 |
| Chao, JY | 1 |
| Chang, CY | 1 |
| Chen, KY | 2 |
| Norman, A | 1 |
| Findlay, M | 1 |
| Watson, M | 1 |
| Nicolson, V | 1 |
| Webb, A | 1 |
| Middleton, G | 1 |
| Ahmed, F | 1 |
| Hickish, T | 1 |
| Aquino, A | 1 |
| Gonnelli, S | 1 |
| Keith, JC | 1 |
| Albert, L | 1 |
| Pfeiffer, CJ | 1 |
| Schaub, RG | 1 |
| Loprinzi, CL | 12 |
| Foote, RL | 1 |
| Michalak, J | 1 |
| Yamao, T | 1 |
| Shimada, Y | 1 |
| Kondo, H | 1 |
| Yokota, T | 1 |
| Sugano, K | 1 |
| Saito, D | 1 |
| Ohkura, H | 1 |
| Yoshida, S | 1 |
| Mochizuki, F | 1 |
| Tomioka, K | 1 |
| Mizuno, Y | 1 |
| Sato, F | 1 |
| Yamagata, T | 1 |
| Nagakawa, Y | 1 |
| Kobari, Y | 1 |
| Iwai, S | 1 |
| Tanaka, T | 1 |
| Mans, DR | 1 |
| Scaletzky, A | 1 |
| Becker, D | 1 |
| de Oliveria, JR | 1 |
| Pinheiro, CM | 1 |
| Bittar, C | 1 |
| Ferreira Filho, A | 1 |
| Machado, VL | 1 |
| Ritt, JL | 1 |
| Jung, FA | 1 |
| Conti, JA | 1 |
| Kemeny, NE | 1 |
| André, AM | 1 |
| Grossano, DD | 1 |
| Bertino, JR | 1 |
| Krause, HH | 1 |
| Breuning, J | 1 |
| Sasaki, T | 1 |
| Ota, K | 1 |
| Taguchi, T | 1 |
| Ogawa, N | 1 |
| Kurihara, M | 1 |
| Akazawa, S | 1 |
| Ogawa, M | 1 |
| Tominaga, T | 1 |
| Konishi, T | 1 |
| Kumai, K | 1 |
| Jebb, SA | 1 |
| Osborne, RJ | 1 |
| Maughan, TS | 1 |
| Mohideen, N | 1 |
| Mack, P | 1 |
| Mort, D | 1 |
| Shelley, MD | 1 |
| Elia, M | 1 |
| Fine, S | 2 |
| Erlichman, C | 3 |
| Kaizer, L | 1 |
| Warr, D | 1 |
| Gadalla, T | 2 |
| Cascinu, S | 2 |
| Fedeli, A | 1 |
| Fedeli, SL | 1 |
| Catalano, G | 2 |
| Metzger, G | 1 |
| Massari, C | 1 |
| Etienne, MC | 1 |
| Comisso, M | 1 |
| Brienza, S | 1 |
| Touitou, Y | 1 |
| Bastian, G | 1 |
| Misset, JL | 2 |
| Lévi, F | 2 |
| Leyvraz, S | 1 |
| Pasche, P | 1 |
| Bauer, J | 1 |
| Bernasconi, S | 1 |
| Monnier, P | 1 |
| Lindquist, L | 1 |
| Stewart, AA | 1 |
| Stam, K | 1 |
| Qu, GY | 1 |
| Iwata, KK | 1 |
| Haley, JD | 2 |
| Scheithauer, W | 2 |
| Depisch, D | 1 |
| Kornek, G | 1 |
| Pidlich, J | 1 |
| Rosen, H | 1 |
| Karall, M | 1 |
| Prochaska, M | 1 |
| Ernst, A | 1 |
| Sebesta, C | 1 |
| Eckhardt, S | 1 |
| Porta, C | 1 |
| Moroni, M | 1 |
| Nastasi, G | 1 |
| Rosso, R | 4 |
| Mazzei, T | 1 |
| Mini, E | 1 |
| Cartei, G | 1 |
| Conte, P | 1 |
| Labianca, R | 2 |
| Cartei, F | 1 |
| Pancera, G | 1 |
| John, WJ | 1 |
| Neefe, JR | 1 |
| Macdonald, JS | 1 |
| Cantrell, J | 1 |
| Smith, M | 1 |
| Tomio, L | 1 |
| Zorat, PL | 1 |
| Segati, R | 1 |
| Loreggian, L | 1 |
| Lora, O | 1 |
| Friso, ML | 1 |
| Chiarion-Sileni, V | 1 |
| Favaretto, A | 1 |
| Fede, A | 1 |
| Rocke, LK | 1 |
| Lee, JK | 2 |
| Kunselman, SJ | 1 |
| Iverson, RK | 1 |
| Finck, G | 1 |
| Lifsey, D | 1 |
| Glaw, KC | 1 |
| Stevens, BA | 1 |
| Hatfield, AK | 2 |
| Adenis, A | 1 |
| Bonneterre, J | 1 |
| Pion, JM | 1 |
| Degardin, M | 1 |
| Horner, D | 1 |
| Seiter, K | 1 |
| Kemeny, N | 1 |
| Martin, D | 1 |
| Schneider, A | 1 |
| Williams, L | 1 |
| Colofiore, J | 1 |
| Sawyer, R | 1 |
| Zalupski, MM | 1 |
| Baker, LH | 1 |
| Zalcberg, JR | 1 |
| Rath, U | 1 |
| Olver, I | 1 |
| Svensson, C | 1 |
| Harper, P | 1 |
| Kerr, D | 1 |
| Perez-Manga, G | 1 |
| Fidler, P | 1 |
| O'Fallon, JR | 2 |
| Leitch, JM | 1 |
| Hayes, DL | 1 |
| Novotny, P | 1 |
| Clemens-Schutjer, D | 2 |
| Bartel, J | 1 |
| Michalak, JC | 3 |
| Shu, CH | 1 |
| Law, CK | 1 |
| Skubitz, KM | 1 |
| Anderson, PM | 1 |
| Del Ferro, E | 1 |
| Ligi, M | 1 |
| Cascino, TL | 1 |
| Veeder, MH | 2 |
| Buckner, JC | 1 |
| Wiesenfeld, M | 1 |
| Levitt, R | 1 |
| Kuross, SA | 1 |
| Morton, RF | 1 |
| Scheithauer, BW | 1 |
| Cleary, JF | 1 |
| Arzoomanian, R | 1 |
| Alberti, D | 2 |
| Feierabend, C | 1 |
| Storer, B | 1 |
| Witt, P | 1 |
| Carbone, P | 1 |
| Wilding, G | 2 |
| Ghosh, C | 1 |
| Camoriano, J | 1 |
| Sloan, J | 1 |
| Steen, PD | 1 |
| Schaefer, PL | 1 |
| Novotny, PJ | 3 |
| Gerstner, JB | 1 |
| White, DF | 1 |
| Quella, SK | 1 |
| Van Vugt, AG | 2 |
| Brien, JP | 1 |
| Muska, AD | 1 |
| Bruskin, AM | 1 |
| Rose, A | 1 |
| Blijham, GH | 1 |
| Sato, A | 1 |
| Kumagai, S | 1 |
| Sakaki, K | 1 |
| Morikawa, H | 1 |
| Song, ST | 1 |
| Mori, S | 1 |
| McDonald, J | 1 |
| Dotoli, E | 1 |
| Schwertschlag, U | 1 |
| Szklut, P | 1 |
| Zambetti, M | 1 |
| Demicheli, R | 1 |
| De Candis, D | 1 |
| Antonelli, G | 1 |
| Giacobone, A | 1 |
| Terenziani, M | 1 |
| Laffranchi, A | 1 |
| Garbagnati, F | 1 |
| Biasi, S | 1 |
| Bonadonna, G | 1 |
| van der Graaf, WT | 1 |
| Spijkervet, FL | 1 |
| Timens, W | 1 |
| Timmer-Bosscha, H | 1 |
| Sluiter, WJ | 1 |
| de Vries, EG | 1 |
| Mulder, NH | 1 |
| Fujii, K | 1 |
| Nakashima, K | 1 |
| Ohno, T | 1 |
| Anai, H | 1 |
| Cao, S | 1 |
| Troutt, AB | 1 |
| Rustum, YM | 2 |
| Chiara, S | 1 |
| Nobile, MT | 2 |
| Vincenti, M | 1 |
| Lionetto, R | 1 |
| Gozza, A | 1 |
| Barzacchi, MC | 1 |
| Sanguineti, O | 1 |
| Repetto, L | 1 |
| Spijkervet, FK | 1 |
| McCarthy, GM | 2 |
| Awde, JD | 1 |
| Ghandi, H | 1 |
| Vincent, M | 1 |
| Kocha, WI | 1 |
| Hudes, GR | 2 |
| Lipsitz, S | 1 |
| Grem, J | 1 |
| Morrisey, M | 1 |
| Weiner, L | 1 |
| Kugler, JW | 1 |
| Benson, A | 1 |
| Loury, D | 1 |
| Embree, JR | 1 |
| Steinberg, DA | 1 |
| Fiddes, JC | 1 |
| Okuno, SH | 1 |
| Woodhouse, CO | 1 |
| Sloan, JA | 3 |
| LaVasseur, BI | 1 |
| Swan, D | 1 |
| Axvig, C | 1 |
| Ebbert, LP | 1 |
| Tirona, MR | 1 |
| Pierson, N | 1 |
| Focan, C | 1 |
| Kreutz, F | 1 |
| Focan-Henrard, D | 1 |
| Lobelle, JP | 1 |
| Adam, R | 1 |
| Dallemagne, B | 1 |
| Jehaes, C | 1 |
| Markiewicz, S | 1 |
| Weerts, J | 1 |
| Bismuth, H | 1 |
| Jasmin, C | 1 |
| Edwards, B | 1 |
| Srpek, L | 1 |
| Wang, HM | 2 |
| Wang, CH | 2 |
| Chen, JS | 2 |
| Su, CL | 1 |
| Liao, CT | 1 |
| Chen, IH | 2 |
| Colevas, AD | 1 |
| Norris, CM | 1 |
| Tishler, RB | 1 |
| Fried, MP | 1 |
| Gomolin, HI | 1 |
| Amrein, P | 1 |
| Nixon, A | 1 |
| Lamb, C | 1 |
| Costello, R | 1 |
| Barton, J | 1 |
| Read, R | 1 |
| Adak, S | 1 |
| Posner, MR | 1 |
| Altmann, S | 1 |
| Hoffmanns, H | 1 |
| Okuno, S | 1 |
| Nair, S | 2 |
| Barton, DL | 1 |
| Riva, C | 1 |
| Lavieille, JP | 1 |
| Schmerber, S | 1 |
| Cuisnie, O | 1 |
| Reyt, E | 1 |
| Meropol, NJ | 1 |
| Creaven, PJ | 1 |
| Blumenson, LE | 1 |
| Frank, C | 1 |
| Cox, JV | 1 |
| Blanke, C | 1 |
| Fehrenbacher, L | 1 |
| Maroun, JA | 2 |
| Ackland, SP | 1 |
| Locker, PK | 1 |
| Pirotta, N | 1 |
| Elfring, GL | 1 |
| Miller, LL | 1 |
| Knox, JJ | 1 |
| Puodziunas, AL | 1 |
| Hoff, PM | 1 |
| Ansari, R | 1 |
| Batist, G | 1 |
| Cox, J | 1 |
| Kocha, W | 1 |
| Kuperminc, M | 1 |
| Maroun, J | 1 |
| Walde, D | 1 |
| Weaver, C | 1 |
| Harrison, E | 1 |
| Burger, HU | 1 |
| Osterwalder, B | 1 |
| Wong, AO | 1 |
| Guglielmi, A | 2 |
| Cirillo, M | 1 |
| Recaldin, E | 1 |
| Aschele, C | 1 |
| Ravaioli, A | 1 |
| Testore, P | 1 |
| Caroti, C | 1 |
| Gallo, L | 2 |
| Pessi, MA | 1 |
| Cortesi, E | 1 |
| Turci, D | 1 |
| Grossi, F | 1 |
| Ng, SH | 1 |
| Liaw, CT | 1 |
| Yang, TS | 1 |
| Melichar, B | 1 |
| Kohout, P | 1 |
| Brátová, M | 1 |
| Solichová, D | 1 |
| Králícková, P | 1 |
| Zadák, Z | 1 |
| Au, E | 1 |
| Koo, WH | 1 |
| Lee, KS | 1 |
| Chua, EJ | 1 |
| Soo, KC | 1 |
| Seow-Choen, F | 1 |
| Low, CH | 1 |
| Ng, BK | 1 |
| Hoe, M | 1 |
| Magné, N | 1 |
| Pivot, X | 1 |
| Marcy, PY | 1 |
| Chauvel, P | 2 |
| Courdi, A | 1 |
| Dassonville, O | 1 |
| Poissonnet, G | 1 |
| Vallicioni, J | 1 |
| Ettore, F | 1 |
| Falewee, MN | 1 |
| Santini, J | 1 |
| Lagrange, JL | 1 |
| Schneider, M | 3 |
| Demard, F | 3 |
| Bensadoun, RJ | 1 |
| Raida, M | 1 |
| Schwabe, W | 1 |
| Häusler, P | 1 |
| Behnke, D | 1 |
| Hejna, M | 1 |
| Köstler, WJ | 1 |
| Raderer, M | 1 |
| Steger, GG | 2 |
| Brodowicz, T | 1 |
| Wiltschke, C | 1 |
| Zielinski, CC | 2 |
| Bell, KA | 1 |
| Perna, AG | 1 |
| Hsu, S | 1 |
| Wenzel, C | 1 |
| Locker, GJ | 1 |
| Schmidinger, M | 1 |
| Mader, R | 1 |
| Kramer, G | 1 |
| Marberger, M | 1 |
| Rauchenwald, M | 1 |
| Bertucci, D | 1 |
| Vargas-Chanes, D | 1 |
| Cha, SS | 1 |
| Poon, MA | 1 |
| Ito, A | 1 |
| Hanawa, T | 1 |
| Fujii, E | 1 |
| Jian, JJ | 1 |
| Cheng, SH | 1 |
| Tsai, SY | 1 |
| Yen, KC | 1 |
| Chu, NM | 1 |
| Chan, KY | 1 |
| Tan, TD | 1 |
| Cheng, JC | 1 |
| Lin, YC | 1 |
| Leu, SY | 1 |
| Hsieh, CI | 1 |
| Tsou, MH | 1 |
| Lin, CY | 1 |
| Huang, AT | 1 |
| Lindquist, SF | 1 |
| Hickey, AJ | 1 |
| Drane, JB | 1 |
| Tattersall, HN | 1 |
| Brodie, GW | 1 |
| Stanford, JR | 1 |
| King, D | 1 |
| Carey, L | 1 |
| Anderson, G | 2 |
| Scialla, SJ | 1 |
| Miskoff, RA | 1 |
| Rees, GJ | 1 |
| Bugaighis, A | 1 |
| Skillings, JR | 1 |
| Steinberg, J | 1 |
| Wong, A | 1 |
| Weh, HJ | 1 |
| Platz, D | 1 |
| Braumann, D | 1 |
| Buggisch, P | 1 |
| Eckardt, N | 1 |
| Schmiegel, WH | 1 |
| Drescher, S | 1 |
| Kleeberg, UR | 1 |
| Müllerleile, U | 1 |
| Crone-Munzebrock, W | 1 |
| Sertoli, MR | 1 |
| Rubagotti, A | 1 |
| Vidili, MG | 1 |
| Venturini, M | 1 |
| Canobbio, L | 1 |
| Fassio, T | 1 |
| Ciais, G | 2 |
| Namer, M | 2 |
| Pourreau-Schneider, N | 2 |
| Martin, PM | 2 |
| Soudry, M | 2 |
| Franquin, JC | 2 |
| Zattara, H | 2 |
| Pazdur, R | 1 |
| Ajani, JJ | 1 |
| Abbruzzese, JL | 1 |
| Belt, RJ | 1 |
| Dakhil, SR | 1 |
| Dubovsky, D | 1 |
| Graham, S | 1 |
| Pilat, S | 1 |
| Winn, R | 1 |
| Levin, B | 1 |
| Weinberger, H | 1 |
| Costa, JW | 1 |
| Evitts, SM | 1 |
| Lindquist, LE | 1 |
| Nicolson, M | 1 |
| Vokes, EE | 2 |
| Haraf, DJ | 1 |
| Panje, WR | 2 |
| Weichselbaum, RR | 2 |
| Bailey, H | 1 |
| Tutsch, KD | 2 |
| Arzoomanian, RZ | 1 |
| Tombes, MB | 1 |
| Grem, JL | 1 |
| Spriggs, DR | 1 |
| Monnet, I | 1 |
| Chariot, P | 1 |
| Azli, N | 1 |
| Ruffié, P | 1 |
| Voisin, S | 1 |
| Saltiel, JC | 1 |
| de Cremoux, H | 1 |
| Cvitkovic, E | 1 |
| Pfeiffer, P | 1 |
| Madsen, EL | 1 |
| Hansen, O | 1 |
| May, O | 1 |
| Tsavaris, NB | 1 |
| Komitsopoulou, P | 1 |
| Tzannou, I | 1 |
| Loucatou, P | 1 |
| Tsaroucha-Noutsou, A | 1 |
| Kilafis, G | 1 |
| Kosmidis, P | 2 |
| Grunberg, SM | 1 |
| Clay, C | 1 |
| Spicer, DV | 1 |
| Anderson, N | 2 |
| Bern, M | 2 |
| Coco, F | 1 |
| Zipoli, T | 1 |
| Moore, C | 2 |
| Gonsalves, L | 1 |
| Elzawawy, A | 1 |
| Saphner, T | 1 |
| Tormey, DC | 1 |
| Albertini, M | 1 |
| Trump, DL | 1 |
| Egorin, MJ | 1 |
| Forrest, A | 1 |
| Willson, JK | 1 |
| Remick, S | 1 |
| Mahood, DJ | 1 |
| Dose, AM | 4 |
| Athmann, LM | 2 |
| Therneau, TM | 2 |
| Sorensen, JM | 1 |
| Gainey, DK | 2 |
| Mailliard, JA | 1 |
| Gusa, NL | 1 |
| Denham, JW | 1 |
| Abbott, RL | 1 |
| Cianflone, SG | 1 |
| Etzell, PS | 1 |
| Burnham, NL | 1 |
| Hagen, L | 1 |
| Cross, M | 1 |
| Evans, WK | 1 |
| Wierzbicki, R | 1 |
| Shepherd, FA | 1 |
| Rusthoven, J | 1 |
| Stewart, DJ | 1 |
| Aitken, SE | 1 |
| Ezzat, A | 1 |
| Tracey, C | 1 |
| Shklar, G | 1 |
| Jenson, J | 1 |
| Florine, D | 1 |
| Wallach, S | 1 |
| Williams, D | 1 |
| LaCreta, F | 1 |
| DeLap, RJ | 1 |
| Grillo-Lopez, AJ | 1 |
| Catalano, R | 1 |
| Comis, RL | 1 |
| Chaffey, J | 1 |
| Neptune, W | 1 |
| Olver, IN | 1 |
| Dalley, D | 1 |
| Woods, R | 1 |
| Aroney, R | 1 |
| Hughes, P | 1 |
| Bishop, JF | 1 |
| Cruickshank, D | 1 |
| Miser, AW | 1 |
| Kardinal, C | 1 |
| Everson, LK | 1 |
| Ahlquist, DA | 1 |
| Dozono, H | 1 |
| Motoya, T | 1 |
| Nakamura, S | 1 |
| Shinmura, R | 1 |
| Miwa, K | 1 |
| Nagata, Y | 1 |
| Mick, R | 1 |
| Awan, AM | 1 |
| Moran, WJ | 1 |
| Goldman, MD | 1 |
| Tybor, AG | 1 |
| Burnham, N | 1 |
| Jabboury, K | 1 |
| Holmes, FA | 1 |
| Hortobagyi, G | 1 |
| Van der Vliet, W | 1 |
| Elhakim, T | 1 |
| Frye, D | 1 |
| Ewer, MS | 1 |
| Fraschini, G | 1 |
| Hug, V | 1 |
| Ames, F | 1 |
| Montague, E | 1 |
| Carrasco, CH | 1 |
| Mackay, B | 1 |
| Legha, SS | 1 |
| Dimery, IW | 1 |
| Rubin, J | 1 |
| Schutt, AJ | 2 |
| Wieand, HS | 1 |
| Becouarn, Y | 1 |
| Calabet, J | 1 |
| Brunet, R | 1 |
| Caballero, GA | 1 |
| Ausman, RK | 1 |
| Quebbeman, EJ | 1 |
| Tsavaris, N | 1 |
| Caragiauris, P | 1 |
| Bertrand, M | 1 |
| Doroshow, JH | 1 |
| Multhauf, P | 1 |
| Blayney, DW | 1 |
| Carr, BI | 1 |
| Cecchi, G | 1 |
| Goldberg, D | 1 |
| Leong, L | 1 |
| Margolin, K | 1 |
| Metter, G | 1 |
| Barone, C | 1 |
| Astone, A | 1 |
| Garufi, C | 1 |
| Grieco, A | 1 |
| Cavallaro, A | 1 |
| Netri, G | 1 |
| Rossi, S | 1 |
| Cassano, A | 1 |
| Ricevuto, E | 1 |
| Noviello, MR | 1 |
| Ensley, JF | 1 |
| Clark, PI | 1 |
| Slevin, ML | 1 |
| Merlano, M | 1 |
| Tatarek, R | 1 |
| Grimaldi, A | 1 |
| Margarino, G | 1 |
| Lokich, JJ | 1 |
| Phillips, D | 1 |
| Green, R | 1 |
| Paul, S | 1 |
| Sonneborn, H | 1 |
| Zipoli, TE | 1 |
| Curt, G | 1 |
| Byfield, JE | 1 |
| Frankel, SS | 1 |
| Hornbeck, CL | 1 |
| Sharp, TR | 1 |
| Callipari, FB | 1 |
| Floyd, RA | 1 |
| Levantine, A | 1 |
| Almeyda, J | 1 |
| Ellerby, RA | 1 |
| Davis, HL | 1 |
| Ramirez, G | 1 |
| Ahmann, DL | 1 |
| Bisel, HF | 1 |
| Dines, DE | 1 |
| Nadler, SH | 2 |
| Moore, GE | 1 |
| Miller, E | 1 |
| Carter, AC | 1 |
| Goldenberg, IS | 1 |
| Segaloff, A | 1 |
| Piro, AJ | 1 |
| Wilson, RE | 1 |
| Hall, TC | 1 |
| Aliapoulios, MA | 1 |
| Nevinny, HB | 1 |
| Moore, FD | 1 |
| Hill, GJ | 1 |
| Grage, TB | 1 |
| Wilson, W | 1 |
| Karev, NI | 1 |
| Blokhina, NG | 1 |
| Vozny, EK | 1 |
| Pershin, MP | 1 |
| White, RS | 1 |
| Fuqua, WB | 1 |
| Barrett, O | 1 |
| Cohen, JL | 1 |
| Krant, MJ | 1 |
| Shnider, BI | 1 |
| Matias, PI | 1 |
| Horton, J | 2 |
| Baxter, D | 1 |
| Olson, KB | 1 |
| Hosley, HF | 1 |
| Brincker, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy[NCT00493636] | Phase 2 | 160 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Prevention of Post-sphincterotomy Bleeding by Endoscopic Tranexamic Acid and Sucralfate Administration: A Randomized Controlled Trial[NCT06107504] | 60 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | |||
| Precise Administration of Sucralfate Powder in Prevention of Delayed Polypectomy Bleeding: a Randomized Clinical Trial[NCT05817656] | Phase 1 | 160 participants (Anticipated) | Interventional | 2023-05-15 | Recruiting | ||
| Microbiota, Inflammatory Environment, Clinical and Radiomic Features as Predictors of Normal Tissue Response in Radiotherapy for Prostate and Head-and-neck Cancer[NCT03294122] | 400 participants (Anticipated) | Observational | 2017-02-02 | Recruiting | |||
| A Polychromatic Light Emitting Diode System to Deliver Low Dose Light Directly Into a Peripheral Intravascular Catheter: A Pain Reduction Study[NCT03246282] | Early Phase 1 | 150 participants (Anticipated) | Interventional | 2017-02-08 | Suspended (stopped due to Lack of Funding) | ||
| The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial[NCT02282839] | Phase 3 | 60 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631] | 43 participants (Actual) | Interventional | 2016-04-25 | Active, not recruiting | |||
| The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939] | Phase 3 | 23 participants (Actual) | Interventional | 2012-09-01 | Active, not recruiting | ||
| Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077] | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050] | Phase 1 | 65 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Evaluation of Dyspeptic Symptoms in Oncological Frail Patients With Extraintestinal Cancer in Chemotherapy. Assessment of Circulating Levels of Glucagon-like Peptide 2 (GLP-2) in Relation to Mucositis[NCT01382667] | 70 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| The Effect of Topical Chamomile in the Prevention of Chemotherapy-induced Oral Mucositis (a Randomized Controlled Clinical Trial)[NCT04317183] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-05-15 | Recruiting | ||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment[NCT03973723] | 441 participants (Actual) | Observational | 2011-08-01 | Completed | |||
| trūFreeze® Spray Cryotherapy Patient Registry[NCT01802203] | 275 participants (Actual) | Observational [Patient Registry] | 2013-04-30 | Completed | |||
| A Phase I Trial of ZD1694 (TOMUDEX® (Registered Trademark)), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease[NCT00001341] | Phase 1 | 60 participants | Interventional | 1993-09-30 | Completed | ||
| Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer[NCT01066741] | Phase 3 | 78 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to insufficient recruitment, the planed sample size appears not achievable) | ||
| Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC[NCT01282658] | 200 participants (Anticipated) | Observational | 2010-11-30 | Recruiting | |||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262] | Phase 3 | 803 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628] | 10 participants (Anticipated) | Interventional | 2012-01-31 | Not yet recruiting | |||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Laser Therapy Associated With Photodynamic Therapy in the Treatment of Oral Mucositis Induced by Chemotherapy in Young Patients: Randomized Blind Clinical Trial[NCT02555501] | Phase 3 | 18 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Multiple Centre, Randomised, Controlled Trial of Hyperfractionated IMRT and Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.[NCT02456506] | 142 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | |||
| Randomized Phase II Study of Recombinant Human Epidermal Growth Factor (rhEGF) on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies[NCT00845819] | Phase 2 | 138 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of overall response was calculated as the time (days) from first documentation of CR or PR (whichever status is recorded first) until the first date that recurrent or progressive disease (PD) or death is objectively documented. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: Period measured from the first documentation of complete or partial response (whichever status is recorded first) until the first date that recurrent or progressive disease or death is objectively documented.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 94 |
| B (Placebo + Gemcitabine or Capecitabine) | 147 |
Overall response rate was defined as the proportion of participants experiencing complete response (CR) and partial response (PR) as best overall response. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: The overall tumor burden at baseline will be compared with subsequent measurements up to the date of first documented disease progression or the date of death due to any cause, if before progression, assessed up to 39 months.
| Intervention | percentage of participants (Number) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 19.8 |
| B (Placebo + Gemcitabine or Capecitabine) | 12.7 |
(NCT00493636)
Timeframe: From the date of randomization to date of death due to any cause, assessed up to 56 months.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 407 |
| B (Placebo + Gemcitabine or Capecitabine) | 348 |
(NCT00493636)
Timeframe: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 103 |
| B (Placebo + Gemcitabine or Capecitabine) | 81 |
(NCT00493636)
Timeframe: Calculated as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical, whichever is earlier), assessed up to 39 months.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 111 |
| B (Placebo + Gemcitabine or Capecitabine) | 82 |
To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years
| Intervention | biomarkers (Number) |
|---|---|
| Reduced Dose Radiation | 0 |
| Standard Dose Radiation | 0 |
MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | -8.12 |
| Standard Dose Radiation | -8.93 |
XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | 2.18 |
| Standard Dose Radiation | 4.38 |
Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 3 |
| Standard Dose Radiation | 1 |
Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| EORTC GHS | EORTC FS | EORTC SS | EORTC HN | |
| Reduced Dose Radiation | 5.95 | 5.14 | -3.91 | -2.80 |
| Standard Dose Radiation | -30.56 | -6.33 | 14.97 | 8.97 |
"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MDASI-HN SI | MDASI-HN SS | |
| Reduced Dose Radiation | 0.64 | 0.52 |
| Standard Dose Radiation | 1.56 | 1.48 |
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| at 3 years | at 5 years | |
| Reduced Dose Radiation | 10 | 10 |
| Standard Dose Radiation | 7 | 7 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
26 reviews available for fluorouracil and Stomatitis
| Article | Year |
|---|---|
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab | 2022 |
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab | 2022 |
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab | 2022 |
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab | 2022 |
S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis.
Topics: Fluorouracil; Humans; Hypokalemia; Hypophosphatemia; Inflammation; Stomach Neoplasms; Stomatitis | 2023 |
Effectiveness of phytotherapeutics in the prevention and treatment of 5-fluorouracil-induced oral mucositis in animal models: A systematic review.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antioxidants; Cricetinae; Fluorouracil; Ma | 2021 |
Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis.
Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Databases, Bibliographic; Disease | 2018 |
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce | 2014 |
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; I | 2016 |
Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy.
Topics: Adult; Antineoplastic Agents; Cryotherapy; Fluorouracil; Hematopoietic Stem Cell Transplantation; Hu | 2015 |
Interaction between capecitabine and brivudin in a patient with breast cancer.
Topics: Aged; Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2011 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap | 2002 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials a | 2003 |
Adjuvant therapy for rectal cancer in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cli | 2004 |
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic | 2004 |
Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clin | 2004 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Capecitabine: a new adjuvant option for colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Cause of Death; Colorectal Neop | 2006 |
Alleviation of cytotoxic therapy-induced normal tissue damage.
Topics: Chlorhexidine; Clinical Trials as Topic; Cryotherapy; Dermatitis; Esophagitis; Eye Diseases; Fluorou | 1995 |
Unexpected fatal toxicity related to low-dose leucovorin with 5-fluorouracil treatment in metastatic colorectal cancer.
Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Pneumonia, Staphylococcal; Sto | 1993 |
New frontiers in the management of chemotherapy-induced mucositis.
Topics: Adult; Animals; Antineoplastic Agents; Cell Division; Child; Cricetinae; Drug Evaluation, Preclinica | 1998 |
Sex differences in fluorouracil-induced stomatitis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Incidence; Male; Middle | 2000 |
Chemotherapy-induced oral mucositis. Prevention and management.
Topics: Antineoplastic Agents; Cryotherapy; Fluorouracil; Humans; Mouth Mucosa; Oral Hygiene; Randomized Con | 2000 |
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Incidence; Logi | 2002 |
Drug reactions. XXIV. Cutaneous reactions to cytostatic agents.
Topics: Alopecia; Aminopterin; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Busulfan; Chlor | 1974 |
The metabolism and pharmacology of 5-fluorouracil.
Topics: Adenocarcinoma; Alopecia; Animals; Breast Neoplasms; Carbon Isotopes; Cell Division; Chromosome Aber | 1971 |
128 trials available for fluorouracil and Stomatitis
| Article | Year |
|---|---|
Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I).
Topics: Aged; Antineoplastic Agents; Cachexia; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; | 2021 |
The chromatographic constitution of andiroba oil and his healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option.
Topics: Animals; Cicatrix; Cricetinae; Fluorouracil; Low-Level Light Therapy; Mesocricetus; Stomatitis | 2023 |
Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemoradiotherapy; Chi-Squ | 2020 |
Effect of cryotherapy in preventing mucositis associated with the use of 5-fluorouracil.
Topics: Antineoplastic Agents; Cryotherapy; Fluorouracil; Humans; Mucositis; Stomatitis | 2020 |
Potential therapeutic effects of different mouthwashes for alleviation and treatment of oral complications of 5-fluorouracil-based chemotherapy in patients with colon cancer.
Topics: Benzydamine; Colonic Neoplasms; Fluorouracil; Glutamine; Humans; Mouthwashes; Pain; Prospective Stud | 2023 |
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colore | 2018 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; | 2013 |
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2013 |
Protective effect of bilberry extract as a pretreatment on induced oral mucositis in hamsters.
Topics: Animals; Cricetinae; Fluorouracil; Photomicrography; Phytotherapy; Plant Extracts; Stomatitis; Vacci | 2013 |
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Breast | 2014 |
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2015 |
A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Doce | 2015 |
Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female | 2016 |
Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female | 2016 |
Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female | 2016 |
Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female | 2016 |
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cultured M | 2008 |
Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea | 2009 |
Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis.
Topics: Adult; Allopurinol; Antimetabolites, Antineoplastic; Double-Blind Method; Female; Fluorouracil; Huma | 2010 |
A prospective, randomized, multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chi-Square Distri | 2010 |
Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.
Topics: Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2012 |
[Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer].
Topics: Adult; Aged; Alginates; Antineoplastic Combined Chemotherapy Protocols; Carnosine; Cisplatin; Doceta | 2011 |
[Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines].
Topics: Alanine; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Mouthwashes; Pilo | 2011 |
Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Double-Blind Method; E | 2012 |
Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy - a randomized controlled trial.
Topics: Antineoplastic Agents; Cryotherapy; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasms; Stoma | 2012 |
Effect of irradiation with red and infrared laser in the treatment of oral mucositis: a pilot study with patients undergoing chemotherapy with 5-FU.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Infra | 2012 |
Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug-Related Side | 2013 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capeci | 2012 |
The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoth | 2013 |
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2002 |
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2002 |
Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial.
Topics: Administration, Oral; Aged; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Double-Blind Method; | 2003 |
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp | 2002 |
Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2003 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non- | 2003 |
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docet | 2004 |
Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Combined Modality Therapy; Diarrhea; Di | 2004 |
Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combi | 2004 |
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Topics: Adult; Aged; Anemia; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2004 |
Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies.
Topics: Adult; Animals; Antifungal Agents; Biological Availability; Body Weight; Chitosan; Cricetinae; Cross | 2004 |
[Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma].
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose | 2004 |
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2004 |
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2005 |
Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil.
Topics: Antimetabolites, Antineoplastic; Attitude to Health; Clinical Nursing Research; Cross-Over Studies; | 2005 |
[Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2005 |
Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chronotherapy; Diarrhe | 2006 |
Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dipeptides; Double-Blind Met | 2006 |
Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Attitude to Health; | 2007 |
The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromi | 2007 |
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administr | 2006 |
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati | 2007 |
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2007 |
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2007 |
[Impact of perioperative chemotherapy on prognosis of colorectal cancer: a report of 82 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2007 |
Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2008 |
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evalu | 1983 |
A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over St | 1995 |
A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplati | 1995 |
Robust Bayesian methods for monitoring clinical trials.
Topics: Bayes Theorem; Clinical Trials as Topic; Data Collection; Data Interpretation, Statistical; Extracor | 1995 |
Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1995 |
Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Chi-Square Distribution; Colorectal Neoplasms; Combined Modality | 1995 |
Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer.
Topics: Adult; Aged; Catheters, Indwelling; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusion Pum | 1995 |
Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
[A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration | 1995 |
5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Double-Bli | 1994 |
Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Diarrhea; Female; Fluor | 1994 |
Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis.
Topics: Adult; Aged; Cryotherapy; Female; Fluorouracil; Humans; Male; Middle Aged; Smoking; Stomatitis | 1994 |
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; | 1994 |
Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms | 1994 |
Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis.
Topics: Adult; Aged; Allopurinol; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Mouthwashes; Stoma | 1994 |
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; | 1994 |
5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Colonic Neoplasms; Drug Admin | 1993 |
A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cryosurgery; Female; | 1993 |
Low-dose, continuous infusion 5-fluorouracil and oral etoposide for the treatment of advanced sarcomas.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration | 1995 |
'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dr | 1995 |
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H | 1996 |
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H | 1996 |
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H | 1996 |
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H | 1996 |
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H | 1996 |
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H | 1996 |
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H | 1996 |
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H | 1996 |
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H | 1996 |
Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 1995 |
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Combined Chemotherapy Proto | 1996 |
A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Colorectal Neopl | 1996 |
Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Astrocytoma; Brain Neoplasms; Female; Fluor | 1996 |
A phase I study of 5-fluorouracil, leucovorin and levamisole.
Topics: Adjuvants, Immunologic; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; | 1997 |
Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy.
Topics: Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Double-Blind Method; Fluorouracil; Humans; Prosp | 1997 |
The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1996 |
[Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Cryotherapy; Deoxyribonucleases; Drug Combinations | 1997 |
Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 1997 |
A new in vitro assay for quantitation of chemotherapy-induced mucositis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami | 1997 |
[Evaluation of 5-fluorouracil concentration in peripheral blood and side effects in continuous hepatic arterial infusion chemotherapy for patients with unresectable liver cancer].
Topics: Abdominal Pain; Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Femal | 1997 |
Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1998 |
A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; | 1999 |
Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy.
Topics: Administration, Oral; Administration, Topical; Aged; Antimetabolites, Antineoplastic; Antineoplastic | 1999 |
Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Clocks; Colonic Neoplasms; C | 1999 |
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Topics: Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 1999 |
Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cohort Studies; Diarr | 1999 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D | 2001 |
Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2001 |
Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Antimetabolites, Antineoplastic; Drug Administration | 2001 |
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; D | 2002 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2002 |
[The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs].
Topics: Aerosols; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplas | 2002 |
Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 1992 |
Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ev | 1992 |
Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma.
Topics: Adult; Aged; Colorectal Neoplasms; Conjunctivitis; Diarrhea; Drug Administration Schedule; Female; F | 1992 |
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Dru | 1992 |
Chemo-related stomatitis on ice.
Topics: Fluorouracil; Humans; Ice; Stomatitis | 1992 |
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Dose-Response Relationshi | 1992 |
Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Double-Blind Meth | 1990 |
Decreased oral toxicity with the local use of allopurinol in patients who received high dose 5-fluorouracil.
Topics: Allopurinol; Fluorouracil; Humans; Mouth Mucosa; Mouthwashes; Stomatitis | 1991 |
Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1991 |
Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo | 1991 |
Inhibition of fluorouracil-induced stomatitis by oral cryotherapy.
Topics: Administration, Oral; Cryosurgery; Drug Synergism; Fluorouracil; Humans; Leucovorin; Mouth Mucosa; P | 1991 |
A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis.
Topics: Allopurinol; Colorectal Neoplasms; Consumer Behavior; Double-Blind Method; Fluorouracil; Humans; Leu | 1990 |
5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Allopurinol; Anorexia; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Esophagit | 1989 |
Cancer control research in the North Central Cancer Treatment Group (NCCTG).
Topics: Allopurinol; Anorexia; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Colorectal Neoplas | 1989 |
[Prevention of stomatitis induced by anti-cancer drugs].
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1989 |
A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1985 |
Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875).
Topics: Audiometry; Cisplatin; Clinical Trials as Topic; Deafness; Digestive System; Drug Evaluation; Drug T | 1974 |
A controlled evaluation of 5-fluorouracil utilizing a single injection technique.
Topics: Adenocarcinoma; Alopecia; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Diseases; Huma | 1974 |
A clinical study of fluorouracil.
Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Le | 1968 |
Corticosteroids and fluorouracil toxicity.
Topics: Bone Marrow; Clinical Trials as Topic; Diarrhea; Digestive System; Fluorouracil; Humans; Injections, | 1966 |
217 other studies available for fluorouracil and Stomatitis
| Article | Year |
|---|---|
Therapeutic Effects of GGsTop
Topics: Aminobutyrates; Animals; Antimetabolites, Antineoplastic; Body Weight; Collagen; Disease Models, Ani | 2021 |
Wound healing process with different photobiomodulation therapy protocols to treat 5-FU-induced oral mucositis in hamsters.
Topics: Animals; Cricetinae; Fluorouracil; Low-Level Light Therapy; Mouth Mucosa; Mucositis; Stomatitis; Wou | 2021 |
Laser Therapy as a Preventive Approach for Oral Mucositis in Cancer Patients Undergoing Chemotherapy: The Potential Role of Superoxide Dismutase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Comparative study of royal jelly, propolis, and photobiomodulation therapies in 5-fluorouracil-related oral mucositis in rats.
Topics: Animals; Fatty Acids; Fluorouracil; Humans; Low-Level Light Therapy; Male; Propolis; Rats; Rats, Wis | 2022 |
Protective effect of endoplasmic reticulum stress inhibition on 5-fluorouracil-induced oral mucositis.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorouracil; | 2022 |
Metformin protects 5-Fu-induced chemotherapy oral mucositis by reducing endoplasmic reticulum stress in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; | 2022 |
The therapeutic effect of bovine colostrum on 5-Fluorouracil-Induced oral mucositis in rats.
Topics: Animals; Cattle; Colostrum; Female; Fluorouracil; Humans; Male; Mouth Mucosa; Pregnancy; Rats; Rats, | 2022 |
Investigation of the protective effect of gel incorporating Eugenia jambolana leaf extract on 5-fluorouracil-induced oral mucositis: an animal study.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Fluorouracil; Gels; Mucositis; Plant Extracts; Rats | 2022 |
Protective Effects of Cannabidiol on Chemotherapy-Induced Oral Mucositis via the Nrf2/Keap1/ARE Signaling Pathways.
Topics: Animals; Antineoplastic Agents; Antioxidants; Cannabidiol; Fluorouracil; Heme Oxygenase-1; Humans; K | 2022 |
Dual roles of ANGPTL4 in multiple inflammatory responses in stomatitis mice.
Topics: Angiopoietin-Like Protein 4; Angiopoietins; Animals; Cytokines; Fluorouracil; Inflammation; Interleu | 2022 |
Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis.
Topics: Animals; Cricetinae; Fluorouracil; Male; Mesocricetus; Mucositis; Ointments; Stomatitis | 2023 |
Sprayable NAHAO® hydrogel alleviates pain and accelerates rat oral mucositis wound healing.
Topics: Animals; Capsaicin; Cyclooxygenase 2; Dinoprostone; Fluorouracil; Humans; Hydrogels; Male; Matrix Me | 2023 |
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da | 2023 |
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da | 2023 |
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da | 2023 |
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da | 2023 |
Fabrication, in Vitro, and in Vivo Characterization of Mucoadhesive Berberine-Loaded Blended Wafers for Treatment of Chemotherapy-Induced Oral Mucositis.
Topics: Alginates; Animals; Antineoplastic Agents; Berberine; Chitosan; Fluorouracil; Hypromellose Derivativ | 2022 |
Fabrication, in Vitro, and in Vivo Characterization of Mucoadhesive Berberine-Loaded Blended Wafers for Treatment of Chemotherapy-Induced Oral Mucositis.
Topics: Alginates; Animals; Antineoplastic Agents; Berberine; Chitosan; Fluorouracil; Hypromellose Derivativ | 2022 |
Fabrication, in Vitro, and in Vivo Characterization of Mucoadhesive Berberine-Loaded Blended Wafers for Treatment of Chemotherapy-Induced Oral Mucositis.
Topics: Alginates; Animals; Antineoplastic Agents; Berberine; Chitosan; Fluorouracil; Hypromellose Derivativ | 2022 |
Fabrication, in Vitro, and in Vivo Characterization of Mucoadhesive Berberine-Loaded Blended Wafers for Treatment of Chemotherapy-Induced Oral Mucositis.
Topics: Alginates; Animals; Antineoplastic Agents; Berberine; Chitosan; Fluorouracil; Hypromellose Derivativ | 2022 |
Characterization of a novel dual murine model of chemotherapy-induced oral and intestinal mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Diarrhea; Disease Models, Animal; Fluorouracil; Intestinal | 2023 |
Anti-Inflammatory Effects of β-Cryptoxanthin on 5-Fluorouracil-Induced Cytokine Expression in Human Oral Mucosal Keratinocytes.
Topics: Anti-Inflammatory Agents; Beta-Cryptoxanthin; Cytokines; Fluorouracil; Humans; Interleukin-6; Interl | 2023 |
Evaluation of the topical gel and oral administration of Punica Granatum Var Pleniflora on oral mucositis induced by 5-Fluorouracil in golden hamsters.
Topics: Administration, Oral; Animals; Cricetinae; Fluorouracil; Male; Mesocricetus; Pomegranate; Stomatitis | 2023 |
The role of Hippophae rhamnoides L. on 5-fluorouracil-ınduced oral mucositis in rats.
Topics: Animals; Antioxidants; Fluorouracil; Hippophae; Interleukin-6; Intestinal Mucosa; Oxidants; Rats; St | 2023 |
1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol ameliorates chemoradiation-induced oral mucositis.
Topics: Animals; Chemokine CXCL2; Chemoradiotherapy; Diglycerides; Fluorouracil; Interleukin-6; Male; Mice; | 2020 |
Glutaryl Melatonin Niosome Gel for Topical Oral Mucositis: Anti- Inflammatory and Anticandidiasis.
Topics: Administration, Topical; Anhydrides; Animals; Anti-Inflammatory Agents; Antifungal Agents; Candida a | 2020 |
Wound Healing Promoting Activity of Tonsil-Derived Stem Cells on 5-Fluorouracil-Induced Oral Mucositis Model.
Topics: Animals; Child; Cricetinae; Culture Media, Conditioned; Disease Models, Animal; Female; Fluorouracil | 2020 |
A Rat Model of Oral Mucositis Induced by Cancer Chemotherapy for Quantitative Experiments.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Fluorouracil; Leukocyte Count; | 2020 |
Cannabidiol on 5-FU-induced oral mucositis in mice.
Topics: Animals; Cannabidiol; Disease Models, Animal; Fluorouracil; Intestinal Mucosa; Mice; Mucositis; Stom | 2020 |
Topical Melatonin Niosome Gel for the Treatment of 5-FU-Induced Oral Mucositis in Mice.
Topics: Animals; Fluorouracil; Liposomes; Melatonin; Mice; Mice, Inbred ICR; Quality of Life; Stomatitis | 2021 |
Anti-inflammatory latex proteins of the medicinal plant Calotropis procera: a promising alternative for oral mucositis treatment.
Topics: Animals; Anti-Inflammatory Agents; Calotropis; Fluorouracil; Latex; Male; Mesocricetus; Plant Protei | 2020 |
Effect of Topical 2% Eucalyptus Extract on 5-FU-Induced Oral Mucositis in Male Golden Hamsters.
Topics: Animals; Cricetinae; Eucalyptus; Fluorouracil; Male; Mesocricetus; Mouth Mucosa; Mucositis; Plant Ex | 2020 |
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit | 2021 |
Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 ameliorates chemotherapy-induced oral mucositis.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Female; Fluorouracil; Inflammation; | 2020 |
The impact of timing and modalities of dental prophylaxis on the risk of 5-fluorouracil-related oral mucositis in patients with head and neck cancer: a nationwide population-based cohort study.
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Dental Prophylaxis; Female; Fluorouracil; Head | 2021 |
Protective effect of Salvia miltiorrhiza Bunge on 5-fluorouracil-induced oral mucositis.
Topics: Animals; Cell Line; Fluorouracil; Humans; Male; Mesocricetus; Plant Extracts; Salvia miltiorrhiza; S | 2017 |
Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); F | 2017 |
Elemental Diet Accelerates the Recovery From Oral Mucositis and Dermatitis Induced by 5-Fluorouracil Through the Induction of Fibroblast Growth Factor 2.
Topics: Animals; Dermatitis; Female; Fibroblast Growth Factor 2; Fluorouracil; Food, Formulated; Glutamine; | 2018 |
Biochemical, hematological, and pathological related healing effects of Elaeagnus angustifolia hydroalcoholic extract in 5-fluorouracil-induced oral mucositis in male golden hamster.
Topics: Animals; Antimetabolites, Antineoplastic; Elaeagnaceae; Fluorouracil; Male; Mesocricetus; Plant Extr | 2017 |
Chemopreventive effects of FITOPROT against 5-fluorouracil-induced toxicity in HaCaT cells.
Topics: Anticarcinogenic Agents; Antioxidants; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Surviva | 2018 |
Role of the route of leukotrienes in an experimental model of oral mucositis induced by 5-fluorouracil 1.
Topics: Animals; Cricetinae; Cysteine; Cytokines; Disease Models, Animal; Fluorouracil; Immunohistochemistry | 2017 |
Protective effect of dexamethasone on 5-FU-induced oral mucositis in hamsters.
Topics: Animals; Cricetinae; Cyclooxygenase 2; Cytokines; Dexamethasone; Fluorouracil; Male; Matrix Metallop | 2017 |
Peroxisome proliferator activated receptor-gamma stimulation for prevention of 5-fluorouracil-induced oral mucositis in mice.
Topics: Animals; Blotting, Western; Cytokines; Fluorouracil; Mice; Mice, Inbred C57BL; Mouth Mucosa; PPAR ga | 2018 |
Therapeutic effect of andiroba oil (Carapa guianensis Aubl.) against oral mucositis: an experimental study in golden Syrian hamsters.
Topics: Animals; Disease Models, Animal; Fluorouracil; Male; Meliaceae; Mesocricetus; Plant Oils; Random All | 2018 |
A Mouse Model for Oral Mucositis Induced by Cancer Chemotherapy.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Disease Models, Animal; Fluor | 2018 |
Chemotherapy-induced oral mucositis and associated infections in a novel organotypic model.
Topics: Adherens Junctions; Apoptosis; Bacteria; Biofilms; Cadherins; Cell Line; Cell Proliferation; Cytokin | 2018 |
Cooling of the oral mucosa to prevent adverse effects of chemotherapeutic agents: An in vitro study.
Topics: Antineoplastic Agents; Cell Survival; Cold Temperature; Cryotherapy; Dose-Response Relationship, Dru | 2018 |
Therapeutic efficacy of rebamipide-loaded PLGA nanoparticles coated with chitosan in a mouse model for oral mucositis induced by cancer chemotherapy.
Topics: Alanine; Animals; Anti-Ulcer Agents; Chitosan; Coated Materials, Biocompatible; Drug Liberation; Flu | 2018 |
Protective effect of angiotensin II receptor blocker against oxidative stress and inflammation in an oral mucositis experimental model.
Topics: Angiotensin Receptor Antagonists; Animals; Antimetabolites, Antineoplastic; Cricetinae; Cytokines; F | 2018 |
Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Antifungal Agents; Antineoplastic Agents; Co | 2018 |
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2018 |
Effects of Onchung-eum, an Herbal Prescription, on 5-Fluorouracil-Induced Oral Mucositis.
Topics: Animals; Cell Death; Cell Survival; Cytokines; Fluorouracil; Herbal Medicine; Humans; Inflammation; | 2018 |
Therapeutic Effect of GGsTop, Selective Gamma-glutamyl Transpeptidase Inhibitor, on a Mouse Model of 5-Fluorouracil-induced Oral Mucositis.
Topics: Aminobutyrates; Animals; Disease Models, Animal; Fluorouracil; gamma-Glutamyltransferase; Humans; Mi | 2019 |
Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cryotherapy; | 2019 |
Mucoadhesive formulation containing Curcuma longa L. reduces oral mucositis induced by 5-fluorouracil in hamsters.
Topics: Animals; Cricetinae; Curcuma; Drug Compounding; Fluorouracil; Male; Mesocricetus; Plant Extracts; St | 2019 |
Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation.
Topics: Amifostine; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Inflammation; Male; Protectiv | 2019 |
Comparison of the efficacy of low-level laser therapy and photodynamic therapy on oral mucositis in rats.
Topics: Animals; Becaplermin; Body Weight; Fibroblast Growth Factor 2; Fluorouracil; Low-Level Light Therapy | 2019 |
Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis.
Topics: Antineoplastic Agents; Bacteria; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Dysb | 2019 |
A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport, Active; Biological Variation, Population; Fem | 2019 |
Effect of rice cell-derived human granulocyte-macrophage colony-stimulating factor on 5-fluorouracil-induced mucositis in hamsters.
Topics: Animals; Antimetabolites, Antineoplastic; Cricetinae; Fluorouracil; Granulocyte-Macrophage Colony-St | 2013 |
Analysis of saliva samples from oncological patients treated with 5-fluorouracil and leucovorin calcium by scanning electron microscopy with energy dispersive system.
Topics: Administration, Intravenous; Adult; Antimetabolites, Antineoplastic; Calcium; Carcinoma; Colonic Neo | 2013 |
Changes of oral microcirculation in chemotherapy patients: A possible correlation with mucositis?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fema | 2014 |
Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Anxiety; Carcinoma; Chemoradiotherapy; Cispl | 2013 |
Alteration of the redox state with reactive oxygen species for 5-fluorouracil-induced oral mucositis in hamsters.
Topics: Animals; Cyclic N-Oxides; Disease Models, Animal; Fluorouracil; Kinetics; Male; Malondialdehyde; Mes | 2013 |
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Colonic N | 2014 |
Platelet-rich fibrin has a healing effect on chemotherapy-induced mucositis in hamsters.
Topics: Administration, Topical; Animals; Blood Platelets; Cricetinae; Disease Models, Animal; Fibrin; Fluor | 2014 |
Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; b | 2014 |
Comparative assessment of the therapeutic effects of the topical and systemic forms of Hypericum perforatum extract on induced oral mucositis in golden hamsters.
Topics: Administration, Oral; Administration, Topical; Animals; Antimetabolites, Antineoplastic; Fluorouraci | 2014 |
Preventive effect of Daiokanzoto (TJ-84) on 5-fluorouracil-induced human gingival cell death through the inhibition of reactive oxygen species production.
Topics: Caspase 1; Cell Death; Drugs, Chinese Herbal; Fluorouracil; Gingiva; Humans; Medicine, Kampo; Reacti | 2014 |
[Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer].
Topics: Adult; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 2014 |
S-nitrosoglutathione accelerates recovery from 5-fluorouracil-induced oral mucositis.
Topics: Administration, Topical; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Gene Expression | 2014 |
Clinical, biochemical and histological study of the effect of antimicrobial photodynamic therapy on oral mucositis induced by 5-fluorouracil in hamsters.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cricetinae; Female; Fluorouracil; Low-Level L | 2015 |
γ-Tocotrienol prevents 5-FU-induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5-FU-induced activation of Nrf2.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Cell Line; Cell Nucleus; Cell Proliferation; Fluorour | 2015 |
Amniotic membrane as a biological dressing for 5-fluoruracil-induced oral mucositis in rats.
Topics: Amnion; Animals; Biological Dressings; Biomarkers; CD4 Lymphocyte Count; CD8 Antigens; Cell Prolifer | 2015 |
Comprehensive Assessment of Host Responses to 5-Fluorouracil-Induced Oral Mucositis through Transcriptomic Analysis.
Topics: Animals; Chitinases; Fluorouracil; Glycoproteins; Interleukin-1beta; Male; Mice; Mice, Inbred BALB C | 2015 |
Hydroalcoholic extract of Carum carvi L. in oral mucositis: a clinical trial in male golden hamsters.
Topics: Animals; Anti-Infective Agents; Carum; Cricetinae; Double-Blind Method; Fluorouracil; Glutathione; M | 2016 |
Photobiomodulation reduces oral mucositis by modulating NF-kB.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cricetinae; Drug Administration Schedul | 2015 |
Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil.
Topics: Acetanilides; Anesthetics, Local; Animals; Anti-Bacterial Agents; Antimetabolites; Carcinosarcoma; C | 2016 |
The therapeutic effects of apigenin and dexamethasone on 5-fluorouracil-induced oral mucositis - a pilot study using a Syrian hamster model.
Topics: Animals; Anti-Inflammatory Agents; Apigenin; Dexamethasone; Disease Models, Animal; Fluorouracil; Ma | 2017 |
A morphometric study of the protective effect of cryotherapy on oral mucositis in cancer patients treated with 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cryotherapy; Female; Fluorouracil; Humans; Male; Middl | 2016 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, | 2016 |
Oral cryotherapy reduced oral mucositis in patients having cancer treatments.
Topics: Cryosurgery; Cryotherapy; Fluorouracil; Humans; Neoplasms; Stomatitis; United States | 2016 |
Effect of a corticosteroid (triamcinolone) and chlorhexidine on chemotherapy-induced oxidative stress in the buccal mucosa of rats.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Chlorhexidine; Female; Fluorouracil; Mouth | 2016 |
Healing acceleration of oral mucositis induced by 5-fluorouracil with Pistacia atlantica (bene) essential oil in hamsters.
Topics: Administration, Topical; Animals; Cricetinae; Fluorouracil; Male; Oils, Volatile; Phytotherapy; Pist | 2017 |
A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Esophageal Neoplasms; Fe | 2017 |
Dosimetric study of photobiomodulation therapy in 5-FU-induced oral mucositis in hamsters.
Topics: Animals; Cricetinae; Fluorouracil; Low-Level Light Therapy; Stomatitis; Wound Healing | 2017 |
Topical application of royal jelly has a healing effect for 5-fluorouracil-induced experimental oral mucositis in hamsters.
Topics: Administration, Topical; Animals; Cricetinae; Fatty Acids; Fluorouracil; Growth Substances; Honey; M | 2008 |
Homogenous amniotic membrane as a biological dressing for oral mucositis in rats: histomorphometric analysis.
Topics: Acetic Acid; Amnion; Animals; Antimetabolites, Antineoplastic; Biological Dressings; Female; Fluorou | 2008 |
Light-emitting diode therapy in chemotherapy-induced mucositis.
Topics: Animals; Antineoplastic Agents; Cheek; Cricetinae; Disease Models, Animal; Fluorouracil; Male; Mesoc | 2008 |
Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cheek; Cri | 2009 |
An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 2009 |
Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal keratinocyte toxicity induced by methotrexate and 5-fluorouracil.
Topics: Allopurinol; Amifostine; Antimetabolites, Antineoplastic; Calcium; Cell Line; Cell Proliferation; Ce | 2009 |
Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis.
Topics: Administration, Buccal; Antimetabolites, Antineoplastic; Betamethasone; Breast Neoplasms; Capecitabi | 2009 |
Effect of oral mucosal adhesive films containing ginsenoside Rb1 on 5-fluorouracil-induced oral mucositis in hamsters.
Topics: Adhesives; Administration, Topical; Alginates; Animals; Antineoplastic Agents; Chitosan; Cricetinae; | 2009 |
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2010 |
Healing action of topical chamomile on 5-fluoracil induced oral mucositis in hamster.
Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Betamethasone; Cricetinae; Female | 2011 |
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa | 2011 |
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2011 |
Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Atorvastatin; Bac | 2011 |
Effects of low-level laser therapy on collagen expression and neutrophil infiltrate in 5-fluorouracil-induced oral mucositis in hamsters.
Topics: Animals; Antimetabolites, Antineoplastic; Collagen; Cricetinae; Female; Fluorouracil; Low-Level Ligh | 2010 |
The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemoradiotherapy; Cisplati | 2011 |
[Early-onset radiation complications and tissue damage in the treatment of head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvant; | 2010 |
Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Fema | 2011 |
Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Beva | 2012 |
Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2012 |
[Elental prevented and reduced oral mucositis during chemotherapy in patients esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female; Fluor | 2011 |
[High incidence-rate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy (FEC100)].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 2012 |
[Concurrent chemoradiotherapy with either CDDP or CDGP, plus 5-FU for squamous cell carcinoma of the oropharynx and hypopharynx].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Protein fraction of Calotropis procera latex protects against 5-fluorouracil-induced oral mucositis associated with downregulation of pivotal pro-inflammatory mediators.
Topics: Animals; Antimetabolites, Antineoplastic; Calotropis; Cricetinae; Cyclooxygenase 2; Cytokines; Disea | 2012 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
Effect of topical chamomile on immunohistochemical levels of IL-1β and TNF-α in 5-fluorouracil-induced oral mucositis in hamsters.
Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Chamomile; Cricetinae; Female; Fl | 2013 |
THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcino | 2012 |
Healing acceleration in hamsters of oral mucositis induced by 5-fluorouracil with topical Calendula officinalis.
Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Calendula; Carboxymethylcellulose Sodium; Criceti | 2013 |
Oral mucosal adhesive films containing royal jelly accelerate recovery from 5-fluorouracil-induced oral mucositis.
Topics: Adhesives; Animals; Cheek; Cricetinae; Fatty Acids; Fibroblast Growth Factor 7; Fluorouracil; Free R | 2013 |
Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cheek; Cricetinae; Dose-Response Relationsh | 2002 |
[The prevention of negative side effects in homeochemotherapy].
Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neop | 2002 |
Long-term results of reirradiation for patients with recurrent rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Topics: Adult; Alopecia; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Topics: Alopecia; Antimetabolites, Antineoplastic; Area Under Curve; Diarrhea; Drug Eruptions; Female; Fever | 2002 |
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Databases, Factual; Diarrhea; Drug | 2003 |
Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis.
Topics: Animals; Bromodeoxyuridine; Cheek; Coloring Agents; Cricetinae; Dose-Response Relationship, Drug; Fi | 2003 |
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
PRELIMINARY OBSERVATIONS ON CARCINOMA OF THE CERVIX TREATED WITH 5-FLUOROURACIL.
Topics: Carcinoma; Female; Fluorouracil; Humans; Injections, Intravenous; Mortality; Neoplasms; Stomatitis; | 1964 |
COMPARISON OF HIGH-DOSAGE AND LOW-DOSAGE-MAINTENANCE THERAPY WITH 5-FLUOROURACIL IN SOLID TUMORS.
Topics: Diarrhea; Fluorouracil; Humans; Nausea; Neoplasms; Stomatitis; Toxicology; Vomiting | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko | 1964 |
[Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2003 |
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 2003 |
An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters.
Topics: Animals; Antimetabolites, Antineoplastic; Basement Membrane; Biopolymers; Blotting, Western; Criceti | 2004 |
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm | 2003 |
[Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2004 |
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bi | 2004 |
Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice.
Topics: Animals; Cisplatin; Dose Fractionation, Radiation; Drug Evaluation, Preclinical; Fibroblast Growth F | 2005 |
Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters.
Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Cricetinae; Disease Models, Animal; Edema; Erythe | 2005 |
Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Cisplatin | 2005 |
Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cryotherapy; F | 2005 |
Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2006 |
Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches.
Topics: Administration, Topical; Animals; Anti-Ulcer Agents; Biomarkers; Cricetinae; Disease Models, Animal; | 2006 |
Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster.
Topics: Animals; Antineoplastic Agents; Cricetinae; Enzyme Inhibitors; Fluorouracil; Guanidines; Immunohisto | 2007 |
Evaluation of topical external medicine for 5-fluorouracil-induced oral mucositis in hamsters.
Topics: Administration, Topical; Alginates; Analysis of Variance; Animals; Anti-Inflammatory Agents; Anti-Ul | 2006 |
Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats.
Topics: Animals; Bifidobacterium; Breath Tests; Disease Models, Animal; Female; Fluorouracil; Ileum; Immunos | 2007 |
Macroscopic and microscopic effects of GaAIAs diode laser and dexamethasone therapies on oral mucositis induced by fluorouracil in rats.
Topics: Aluminum; Animals; Anti-Inflammatory Agents; Antimetabolites; Arsenicals; Biofilms; Dexamethasone; D | 2007 |
Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster.
Topics: Animals; Antimetabolites, Antineoplastic; Cricetinae; Dipeptides; Fluorouracil; Glutamine; Glutathio | 2008 |
In vivo imaging of oral mucositis in an animal model using optical coherence tomography and optical Doppler tomography.
Topics: Animals; Blood Flow Velocity; Cricetinae; Disease Models, Animal; Fluorouracil; Mesocricetus; Mouth | 2007 |
Questions about the role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cryotherapy; Data Interpretati | 2007 |
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 2007 |
Allopurinol modulation of fluorouracil toxicity.
Topics: Allopurinol; Drug Eruptions; Drug Therapy, Combination; Fluorouracil; Hematologic Diseases; Humans; | 1981 |
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce | 1984 |
MTX/5-FU trials in gastrointestinal and other cancers.
Topics: Aged; Anemia; Conjunctivitis; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Gastrointest | 1983 |
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Cy | 1984 |
Phase I study of protracted venous infusion of 5-fluorouracil.
Topics: Adult; Aged; Catheters, Indwelling; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Admini | 1981 |
Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow; Cricetinae; Dose-Response Relationship, Drug; | 1995 |
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Evalua | 1993 |
IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology.
Topics: Acetates; Acetic Acid; Animals; Animals, Genetically Modified; beta 2-Microglobulin; Colitis; Cricet | 1994 |
[Two patients with far advanced gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1995 |
Two new cases of hyperpyrimidinuria associated with excessive 5-fluorouracil toxicity.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Leukopenia; Mouth Mucosa; Pyrimidines; Stomatitis | 1994 |
[Allopurinol].
Topics: Allopurinol; Fluorouracil; Humans; Mouth Mucosa; Stomatitis | 1995 |
Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3.
Topics: Animals; Cell Cycle; Cell Division; CHO Cells; Cricetinae; Disease Models, Animal; DNA; Epithelial C | 1994 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Drug Synergism | 1993 |
Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis.
Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Biomarkers; Cell Division; Cricet | 1997 |
Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters.
Topics: Animals; Blood Cell Count; Bone Marrow Cells; Cricetinae; Fluorouracil; Interleukin-11; Male; Mesocr | 1997 |
Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; Flu | 1998 |
Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Digestive System Ne | 1998 |
Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters.
Topics: Animals; Anti-Infective Agents, Local; Antimicrobial Cationic Peptides; Bacillus; Colony Count, Micr | 1999 |
Evaluation of bovine lactoferrin as a topical therapy for chemotherapy-induced mucositis in the golden Syrian hamster.
Topics: Animals; Antimetabolites, Antineoplastic; Cheek; Cricetinae; Drug Evaluation; Fluorouracil; Immunoco | 1999 |
Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Asia, Southeastern; Cisplatin; F | 1999 |
Intestinal permeability in patients with chemotherapy-induced stomatitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Digestive System Neoplasms | 2001 |
Adjuvant postoperative 5-fluorouracil chemotherapy combined with pelvic radiation for rectal cancer: results from an Asian population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Agranulocytosis; Antimetabolites, Antineoplastic; Ch | 2001 |
[Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2001 |
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Topics: Adult; Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neopla | 2001 |
Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil | 2001 |
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); | 2002 |
Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2002 |
Effect of oral hygiene on stomatitis in patients receiving cancer chemotherapy.
Topics: Breast Neoplasms; Cyclophosphamide; Dental Plaque; Doxorubicin; Female; Fluorouracil; Humans; Inject | 1978 |
Allopurinol modulation of high-dose fluorouracil toxicity.
Topics: Allopurinol; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leukopenia | 1979 |
The adverse effects of elemental diets on tolerance for 5-FU toxicity in the rat.
Topics: Amino Acids, Essential; Animals; Blood; Blood Proteins; Body Weight; Colon; Diarrhea; Diet; Dietary | 1977 |
Basal-cell carcinoma. A case unmasked by systemic fluorouracil therapy.
Topics: Administration, Topical; Carcinoma, Basal Cell; Diarrhea; Fluorouracil; Humans; Injections, Intraven | 1976 |
Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil.
Topics: Alopecia; Carcinoma, Bronchogenic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1975 |
Orofacial complications of chemotherapy for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Candidiasis, Oral; Chi-Squa | 1992 |
[Laser therapy in the prevention and treatment of mucositis caused by anticancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Laser Thera | 1992 |
Cryotherapy used to reduce stomatitis.
Topics: Cryosurgery; Fluorouracil; Humans; Incidence; Research Design; Stomatitis | 1992 |
Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy.
Topics: Animals; Cell Division; Cricetinae; Epidermal Growth Factor; Epithelial Cells; Epithelium; Fluoroura | 1992 |
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H | 1992 |
Severe mucositis after chemotherapy with vinorelbine, 5-fluorouracil, leucovorin and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Fluoroura | 1991 |
Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: a preliminary report.
Topics: Female; Fluorouracil; Humans; Iatrogenic Disease; Laser Therapy; Male; Middle Aged; Mouth Mucosa; Ne | 1992 |
Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Drug Eruptions; Drug Tolerance; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1991 |
Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes.
Topics: Allopurinol; Fluorouracil; Gastrointestinal Neoplasms; Humans; Mouthwashes; Stomatitis | 1991 |
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.
Topics: Bone Marrow Diseases; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Fluorouraci | 1991 |
Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1991 |
An animal model for mucositis induced by cancer chemotherapy.
Topics: Animals; Cricetinae; Disease Models, Animal; Epithelium; Fluorouracil; Leukopenia; Male; Mesocricetu | 1990 |
Studies on the prevention of 5-fluorouracil-induced oral mucositis.
Topics: Allopurinol; Cryosurgery; Fluorouracil; Humans; Mouth Mucosa; Mouthwashes; Stomatitis | 1990 |
A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Demonstration of biochemical modulation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admin | 1989 |
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Chro | 1989 |
Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1989 |
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino | 1989 |
Allopurinol mouthwash as prophylactic therapy for 5-fluorouracil-induced mucositis.
Topics: Administration, Oral; Allopurinol; Fluorouracil; Humans; Mouth Mucosa; Stomatitis | 1989 |
5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; M | 1989 |
Allopurinol mouthwash for prevention of fluorouracil-induced stomatitis.
Topics: Allopurinol; Breast Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Mouthwashes; | 1989 |
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyc | 1989 |
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo | 1985 |
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1986 |
Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Colonic Neoplasms; Diarrhea; D | 1988 |
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil | 1985 |
Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes.
Topics: Allopurinol; Fluorouracil; Gastrointestinal Neoplasms; Humans; Mouth Mucosa; Mouthwashes; Stomatitis | 1988 |
High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1986 |
High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Fl | 1987 |
Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity.
Topics: Allopurinol; Colonic Neoplasms; Fluorouracil; Humans; Intestinal Mucosa; Mouth Mucosa; Mouthwashes; | 1985 |
Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Ce | 1985 |
5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sc | 1985 |
Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man.
Topics: Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Nausea; Neoplasms; Neutr | 1985 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
Phase I study of phenesterin (NSC-104469).
Topics: Administration, Oral; Adult; Aged; Androgens; Antineoplastic Agents; Blood Cell Count; Blood Platele | 1971 |
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
Topics: Adrenalectomy; Adult; Aged; Alopecia; Ataxia; Blood Platelet Disorders; Breast Neoplasms; Diarrhea; | 1972 |
5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
Topics: Adult; Aged; Breast Neoplasms; Diarrhea; Evaluation Studies as Topic; Female; Fluorouracil; Gastroin | 1972 |
Experience with ftorafur treatment in breast cancer.
Topics: Breast Neoplasms; Diarrhea; Female; Fluorouracil; Furans; Humans; Injections, Intravenous; Leukopeni | 1972 |
The effect of 5-fluorouracil on small bowel mucosa.
Topics: Adult; Aged; Biopsy; Diarrhea; Duodenum; Female; Fluorouracil; Humans; Intestinal Mucosa; Intestine, | 1971 |
Radiation plus 5-fluorouracil (NSC-19893): clinical demonstration of an additive effect in bronchogenic carcinoma.
Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Female; Fluorouracil; Human | 1971 |
[Combined cytostatic treatment of solid tumours with cyclophosphamide (Endoxan), vincristine, methylaminopterin (Methotrexate) and 5-fluorouracil].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Cyclophosphami | 1971 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |